var images_info;if (!images_info) images_info =[]; images_info["117"]={"117024":{"type":"graphic_movie","displayName":"Bascom cleft lift procedure","title":"Bascom cleft lift procedure","html":"<div class=\"graphic normal\"><div style=\"width: 740px\" class=\"figure\"><div class=\"ttl\">Bascom cleft lift procedure</div><div class=\"cntnt\"><div class=\"videoplayer\" h264=\"images/SURG/117024_Bascomcleftliftprcdrvid.mp4\" style=\"width:720px;height:560px\"></div><img style=\"width:644px; height:528px;\" src=\"images/SURG/117024_Bascomcleftliftprcdrimg.jpg\" alt=\"Image\"/></div><div class=\"graphic_reference\">Reprinted by permission from: Springer. Johnson EK. Pilonidal disease and hidradenitis suppurativa. In: The ASCRS Textbook of Colon and Rectal Surgery, 3rd ed, Steele SR, Hull TL, Read TE, et al. (Eds), Springer 2016. Copyright &copy; 2016. <a href=\"https://link.springer.com/book/10.1007/978-3-319-25970-3\" target=\"_blank\">https://link.springer.com/book/10.1007/978-3-319-25970-3</a>.</div><div id=\"graphicVersion\">Graphic 117024 Version 1.0</div></div></div>"},"117027":{"type":"graphic_table","displayName":"Dietary cariogenicity","title":"Summary of dietary characteristics on cariogenicity","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Summary of dietary characteristics on cariogenicity</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"3\" width=\"33%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Dietary characteristic</td> <td class=\"subtitle1\">Examples</td> <td class=\"subtitle1\">Impact on cariogenicity</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"3\">Macronutrient composition</td> </tr> <tr> <td class=\"indent1\" colspan=\"3\"><strong>Carbohydrate composition of food item</strong></td> </tr> <tr> <td class=\"indent2\"> <ul> <li>Sugars </li> </ul> </td> <td> <ul> <li>Table sugar </li> <li>Honey </li> <li>Maple syrup </li> </ul> </td> <td>Increased &ndash; readily fermented</td> </tr> <tr> <td class=\"indent2\"> <ul> <li>Starch </li> </ul> </td> <td> <ul> <li>Potatoes </li> <li>Rice </li> </ul> </td> <td>Increased &ndash; slowly fermented</td> </tr> <tr> <td class=\"indent2\"> <ul> <li>Modified starch* </li> </ul> </td> <td> <ul> <li>NA </li> </ul> </td> <td>Increased &ndash; readily fermented</td> </tr> <tr> <td class=\"indent2\"> <ul> <li>Combined (sugar&nbsp;plus modified starch and/or starch) </li> </ul> </td> <td> <ul> <li>Pastries </li> <li>Cookies </li> <li>Crackers </li> </ul> </td> <td>Increased</td> </tr> <tr> <td class=\"indent2\"> <ul> <li>Carbohydrate&nbsp;plus protein and/or fat </li> </ul> </td> <td> <ul> <li>Pizza </li> <li>Yogurt </li> </ul> </td> <td>Decreased</td> </tr> <tr> <td class=\"indent1\" colspan=\"3\"><strong>Meal/snack composition</strong></td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent2\"> <ul> <li>Inclusion of foods containing protein or fat </li> </ul> </td> <td> <ul> <li>Eggs and toast </li> <li>Meat, potatoes, and broccoli </li> <li>Sweet snack followed by nuts or cheese </li> </ul> </td> <td>Decreased</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"3\">Oral clearance</td> </tr> <tr> <td class=\"indent1\">Rapid</td> <td> <ul> <li>Sugar-sweetened beverages </li> </ul> </td> <td>Decreased</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Slow</td> <td> <ul> <li>Baked sweets </li> <li>Salty snacks </li> <li>Sticky foods (eg, jelly beans, taffy, raisins, sugar-containing chewing gum) </li> </ul> </td> <td>Increased</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"3\">Meal patterns</td> </tr> <tr> <td class=\"indent1\">Prolonged eating events</td> <td> <ul> <li>NA </li> </ul> </td> <td>Increased</td> </tr> <tr> <td class=\"indent1\">Frequent eating events</td> <td> <ul> <li>NA </li> </ul> </td> <td>Increased</td> </tr> <tr> <td class=\"indent1\">Structured/scheduled meals and snacks<sup>&#182;</sup></td> <td> <ul> <li>NA </li> </ul> </td> <td>Decreased</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">NA: not applicable.<br />* Starches modified by the food industry (eg, chemically, enzymatically, physically) to change properties (eg, for use as a thickening agent).<br />&para; Structured meals and snacks allow time for the acid levels in the mouth to return to normal between eating events.</div><div class=\"graphic_reference\">Courtesy of Teresa A Marshall, PhD, Arthur J Nowak, DMD, and John J Warren, DDS, University of Iowa College of Dentistry and Dental Clinics.</div><div id=\"graphicVersion\">Graphic 117027 Version 1.0</div></div></div>"},"117050":{"type":"graphic_figure","displayName":"Structures of the retroperitoneum","title":"Structures of the retroperitoneum","html":"<div class=\"graphic\"><div style=\"width: 548px\" class=\"figure\"><div class=\"ttl\">Structures of the retroperitoneum</div><div class=\"cntnt\"><img style=\"width:528px; height:486px;\" src=\"images/SURG/117050_Structuresoftheretroperitoneum.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The retroperitoneum is the space just posterior to the peritoneal cavity and anterior to the paraspinous musculature (eg, psoas and quadratus lumborum, bilaterally). Superiorly, the retroperitoneum is bordered by the diaphragm, and inferiorly, it forms a natural extension into the pelvis. The retroperitoneum includes the bilateral kidneys and adrenal glands, perirenal fat, aorta, vena cava, and iliac vessels as well as the duodenum and pancreas. The ascending and descending colon are considered partially retroperitoneal. </div><div id=\"graphicVersion\">Graphic 117050 Version 1.0</div></div></div>"},"117055":{"type":"graphic_table","displayName":"Crude incidence rates without and with atrial fibrillation","title":"Crude incidence rates at one-year of follow-up in the Heart Failure Study Population, stratified according to prior diagnosis of atrial fibrillation*","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Crude incidence rates at one-year of follow-up in the Heart Failure Study Population, stratified according to prior diagnosis of atrial fibrillation*</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup width=\"19.5%\"></colgroup><colgroup span=\"7\" width=\"11.5%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\" rowspan=\"2\">End points</td> <td class=\"subtitle1\" rowspan=\"2\">Overall</td> <td class=\"subtitle1\" colspan=\"6\">Number of additional risk factors on CHA<sub>2</sub>DS<sub>2</sub>-VASc score</td> </tr> <tr> <td class=\"subtitle2\">1 (HF only)</td> <td class=\"subtitle2\">2</td> <td class=\"subtitle2\">3</td> <td class=\"subtitle2\">4</td> <td class=\"subtitle2\">5</td> <td class=\"subtitle2\">&#8805;6</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"8\">Patients without atrial fibrillation</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Patients, number (%)</td> <td class=\"centered\">33,592</td> <td class=\"centered\">2366 (7.0)</td> <td class=\"centered\">4503 (13.4)</td> <td class=\"centered\">7462 (22.2)</td> <td class=\"centered\">9183 (27.3)</td> <td class=\"centered\">5958 (17.7)</td> <td class=\"centered\">4120 (12.3)</td> </tr> <tr> <td class=\"indent1\" colspan=\"8\">Ischemic stroke</td> </tr> <tr> <td class=\"indent2\">Events, number</td> <td class=\"centered\">977</td> <td class=\"centered\">29</td> <td class=\"centered\">62</td> <td class=\"centered\">141</td> <td class=\"centered\">258</td> <td class=\"centered\">212</td> <td class=\"centered\">275</td> </tr> <tr> <td class=\"indent2\">Person-years, number</td> <td class=\"centered\">9,448,812</td> <td class=\"centered\">711,473</td> <td class=\"centered\">1,393,807</td> <td class=\"centered\">2,180,746</td> <td class=\"centered\">2,529,593</td> <td class=\"centered\">1,599,137</td> <td class=\"centered\">707,004</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent2\">Incidence rate, % (95% CI)</td> <td class=\"centered\">1.0 (1.0-1.1)</td> <td class=\"centered\">0.4 (0.3-0.6)</td> <td class=\"centered\">0.4 (0.3-0.6)</td> <td class=\"centered\">0.6 (0.5-0.8)</td> <td class=\"centered\">1.0 (0.9-1.2)</td> <td class=\"centered\">1.3 (1.2-1.5)</td> <td class=\"centered\">2.6 (2.4-3.0)</td> </tr> <tr> <td class=\"indent1\" colspan=\"8\">Thromboembolism<sup>&#182;</sup></td> </tr> <tr> <td class=\"indent2\">Events, number</td> <td class=\"centered\">3187</td> <td class=\"centered\">110</td> <td class=\"centered\">276</td> <td class=\"centered\">548</td> <td class=\"centered\">853</td> <td class=\"centered\">683</td> <td class=\"centered\">717</td> </tr> <tr> <td class=\"indent2\">Person-years, number</td> <td class=\"centered\">9,040,950</td> <td class=\"centered\">696,366</td> <td class=\"centered\">1,348,456</td> <td class=\"centered\">2,104,494</td> <td class=\"centered\">2,421,856</td> <td class=\"centered\">1,518,482</td> <td class=\"centered\">652,067</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent2\">Incidence rate, % (95% CI)</td> <td class=\"centered\">3.5 (3.4-3.6)</td> <td class=\"centered\">1.6 (1.3-1.9)</td> <td class=\"centered\">2.0 (1.8-2.3)</td> <td class=\"centered\">2.6 (2.4-2.8)</td> <td class=\"centered\">3.5 (3.3-3.8)</td> <td class=\"centered\">4.5 (4.2-4.8)</td> <td class=\"centered\">7.5 (7.0-8.1)</td> </tr> <tr> <td class=\"indent1\" colspan=\"8\">Death</td> </tr> <tr> <td class=\"indent2\">Events, number</td> <td class=\"centered\">6956</td> <td class=\"centered\">149</td> <td class=\"centered\">332</td> <td class=\"centered\">1256</td> <td class=\"centered\">2239</td> <td class=\"centered\">1596</td> <td class=\"centered\">1384</td> </tr> <tr> <td class=\"indent2\">Person-years, number</td> <td class=\"centered\">9,596,399</td> <td class=\"centered\">715,795</td> <td class=\"centered\">1,404,213</td> <td class=\"centered\">2,201,781</td> <td class=\"centered\">2,566,123</td> <td class=\"centered\">1,632,315</td> <td class=\"centered\">731,311</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent2\">Incidence rate, % (95% CI)</td> <td class=\"centered\">7.2 (7.1-7.4)</td> <td class=\"centered\">2.1 (1.8-2.4)</td> <td class=\"centered\">2.4 (2.1-2.6)</td> <td class=\"centered\">5.7 (5.4-6.0)</td> <td class=\"centered\">8.7 (8.4-9.1)</td> <td class=\"centered\">9.8 (9.3-10.3)</td> <td class=\"centered\">12.9 (12.2-13.6)</td> </tr> <tr class=\"divider_top\"> <td class=\"subtitle2_left\" colspan=\"8\">Patients with atrial fibrillation</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Patients, number (%)</td> <td class=\"centered\">9395</td> <td class=\"centered\">606 (6.5)</td> <td class=\"centered\">931 (9.9)</td> <td class=\"centered\">1752 (18.7)</td> <td class=\"centered\">2571 (27.4)</td> <td class=\"centered\">137 (20.6)</td> <td class=\"centered\">1598 (17.0)</td> </tr> <tr> <td class=\"indent1\" colspan=\"8\">Ischemic stroke</td> </tr> <tr> <td class=\"indent2\">Events, number</td> <td class=\"centered\">318</td> <td class=\"centered\">8</td> <td class=\"centered\">11</td> <td class=\"centered\">32</td> <td class=\"centered\">82</td> <td class=\"centered\">80</td> <td class=\"centered\">105</td> </tr> <tr> <td class=\"indent2\">Person-years, number</td> <td class=\"centered\">1,592,497</td> <td class=\"centered\">55,019</td> <td class=\"centered\">110,265</td> <td class=\"centered\">294,757</td> <td class=\"centered\">477,528</td> <td class=\"centered\">365,633</td> <td class=\"centered\">180,083</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent2\">Incidence rate, % (95% CI)</td> <td class=\"centered\">2.0 (1.8-2.2)</td> <td class=\"centered\">1.5 (0.7-2.9)</td> <td class=\"centered\">1.0 (0.6-1.8)</td> <td class=\"centered\">1.1 (0.8-1.5)</td> <td class=\"centered\">1.7 (1.4-2.1)</td> <td class=\"centered\">2.2 (1.8-2.7)</td> <td class=\"centered\">3.6 (3.0-4.4)</td> </tr> <tr> <td class=\"indent1\" colspan=\"8\">Thromboembolism<sup>&#182;</sup></td> </tr> <tr> <td class=\"indent2\">Events, number</td> <td class=\"centered\">651</td> <td class=\"centered\">18</td> <td class=\"centered\">31</td> <td class=\"centered\">85</td> <td class=\"centered\">158</td> <td class=\"centered\">169</td> <td class=\"centered\">190</td> </tr> <tr> <td class=\"indent2\">Person-years, number</td> <td class=\"centered\">1,551,095</td> <td class=\"centered\">54,425</td> <td class=\"centered\">107,277</td> <td class=\"centered\">287,648</td> <td class=\"centered\">468,813</td> <td class=\"centered\">357,479</td> <td class=\"centered\">172,156</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent2\">Incidence rate, % (95% CI)</td> <td class=\"centered\">4.2 (3.9-4.5)</td> <td class=\"centered\">3.3 (2.1-5.2)</td> <td class=\"centered\">2.9 (2.0-4.1)</td> <td class=\"centered\">3.0 (2.4-3.7)</td> <td class=\"centered\">3.4 (2.9-3.9)</td> <td class=\"centered\">4.7 (4.1-5.5)</td> <td class=\"centered\">6.9 (6.0-8.0)</td> </tr> <tr> <td class=\"indent1\" colspan=\"8\">Death</td> </tr> <tr> <td class=\"indent2\">Events, number</td> <td class=\"centered\">2153</td> <td class=\"centered\">11</td> <td class=\"centered\">47</td> <td class=\"centered\">282</td> <td class=\"centered\">677</td> <td class=\"centered\">561</td> <td class=\"centered\">575</td> </tr> <tr> <td class=\"indent2\">Person-years, number</td> <td class=\"centered\">1,630,977</td> <td class=\"centered\">55,347</td> <td class=\"centered\">111,192</td> <td class=\"centered\">297,304</td> <td class=\"centered\">489,042</td> <td class=\"centered\">373,574</td> <td class=\"centered\">186,490</td> </tr> <tr> <td class=\"indent2\">Incidence rate, % (95% CI)</td> <td class=\"centered\">13.2 (12.7-13.8)</td> <td class=\"centered\">2.0 (1.1-3.6)</td> <td class=\"centered\">4.2 (3.2-5.6)</td> <td class=\"centered\">9.5 (8.4-10.7)</td> <td class=\"centered\">13.8 (12.8-14.9)</td> <td class=\"centered\">15.0 (13.8-16.3)</td> <td class=\"centered\">18.9 (17.4-20.5)</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">HF: heart failure.<br />* CHA<sub>2</sub>DS<sub>2</sub>-VASc score is calculated as congestive heart failure (1 point), hypertension (1 point), age 75 years or older (2 points), diabetes (1 point), stroke/transient ischemic attack/thromboembolism (2 points), vascular disease (prior myocardial infarction, peripheral artery disease, or aortic plaque; 1 point), age 65 to 75 years (1 point), female sex (1 point). All study patients had heart failure at baseline.<br />&para; Composite end point of ischemic stroke, transient ischemic attack, systemic embolism, pulmonary embolism, or acute myocardial infarction.</div><div class=\"graphic_reference\">Reproduced with permission from: Melgaard L, Gorst-Rasmussen A, Lane DA, et al. Assessment of the CHA2DS2-VASc Score in Predicting Ischemic Stroke, Thromboembolism, and Death in Patients With Heart Failure With and Without Atrial Fibrillation. JAMA 2015; 314:1030. Copyright &copy; 2015 American Medical Association. All rights reserved.</div><div id=\"graphicVersion\">Graphic 117055 Version 1.0</div></div></div>"},"117057":{"type":"graphic_picture","displayName":"Pilonidal disease masquerading as possible anal fistula","title":"Pilonidal disease masquerading as possible anal fistula","html":"<div class=\"graphic\"><div style=\"width: 585px\" class=\"figure\"><div class=\"ttl\">Pilonidal disease masquerading as possible anal fistula</div><div class=\"cntnt\"><img style=\"width:565px; height:754px;\" src=\"images/SURG/117057_Plndldmsqrdgpsblnlfstl.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Complex pilonidal disease. The patient is prone. (A) is the original pilonidal sinus; (B) represents a secondary opening as a result of disease progression. Having multiple openings creates confusion in the diagnosis in this patient,&nbsp;in whom pilonidal disease masquerades as an anal fistula.</div><div class=\"graphic_reference\">Reprinted by permission from: Springer. Johnson EK. Pilonidal disease and hidradenitis suppurativa. In: The ASCRS Textbook of Colon and Rectal Surgery, 3rd ed, Steele SR, Hull TL, Read TE, et al. (Eds), Springer 2016. Copyright &copy; 2016. <a href=\"https://link.springer.com/book/10.1007/978-3-319-25970-3\" target=\"_blank\">https://link.springer.com/book/10.1007/978-3-319-25970-3</a>.</div><div id=\"graphicVersion\">Graphic 117057 Version 1.0</div></div></div>"},"117058":{"type":"graphic_movie","displayName":"Rhomboid flap pilonidal","title":"Rhomboid flap pilonidal","html":"<div class=\"graphic normal\"><div style=\"width: 548px\" class=\"figure\"><div class=\"ttl\">Rhomboid flap pilonidal</div><div class=\"cntnt\"><div class=\"videoplayer\" h264=\"images/SURG/117058_Rhomboidflappilonidalvid.mp4\" style=\"width:528px;height:416px\"></div><img style=\"width:644px; height:561px;\" src=\"images/SURG/117058_Rhomboidflappilonidalimg.jpg\" alt=\"Image\"/></div><div class=\"graphic_reference\">Reprinted by permission from: Springer. Johnson EK. Pilonidal disease and hidradenitis suppurativa. In: The ASCRS Textbook of Colon and Rectal Surgery, 3rd ed, Steele SR, Hull TL, Read TE, et al. (Eds), Springer 2016. Copyright &copy; 2016. <a href=\"https://link.springer.com/book/10.1007/978-3-319-25970-3\" target=\"_blank\">https://link.springer.com/book/10.1007/978-3-319-25970-3</a>.</div><div id=\"graphicVersion\">Graphic 117058 Version 1.0</div></div></div>"},"117059":{"type":"graphic_picture","displayName":"Moderate-to-severe chronic pilonidal disease","title":"Moderate-to-severe chronic pilonidal disease","html":"<div class=\"graphic\"><div style=\"width: 774px\" class=\"figure\"><div class=\"ttl\">Moderate-to-severe chronic pilonidal disease</div><div class=\"cntnt\"><img style=\"width:754px; height:564px;\" src=\"images/SURG/117059_Mdtsvrchrncpilonidalds.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Typical appearance of moderate-to-severe chronic pilonidal disease with the patient prone and buttock cheeks retracted apart with tape.</div><div class=\"graphic_reference\">Reprinted by permission from: Springer. Johnson EK. Pilonidal disease and hidradenitis suppurativa. In: The ASCRS Textbook of Colon and Rectal Surgery, 3rd ed, Steele SR, Hull TL, Read TE, et al. (Eds), Springer 2016. Copyright &copy; 2016. <a href=\"https://link.springer.com/book/10.1007/978-3-319-25970-3\" target=\"_blank\">https://link.springer.com/book/10.1007/978-3-319-25970-3</a>.</div><div id=\"graphicVersion\">Graphic 117059 Version 1.0</div></div></div>"},"117060":{"type":"graphic_picture","displayName":"Completed and healed rhomboid flap","title":"Completed and healed rhomboid flap","html":"<div class=\"graphic\"><div style=\"width: 583px\" class=\"figure\"><div class=\"ttl\">Completed and healed rhomboid flap</div><div class=\"cntnt\"><img style=\"width:563px; height:751px;\" src=\"images/SURG/117060_Completedhealedrhombdflp.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Photo of a healed rhomboid flap excision of pilonidal disease. The patient is prone. Refer to related UpToDate topic for a description and video of this technique.</div><div id=\"graphicVersion\">Graphic 117060 Version 2.0</div></div></div>"},"117062":{"type":"graphic_picture","displayName":"Completed rhomboid flap with dressing","title":"Completed rhomboid flap with dressing","html":"<div class=\"graphic\"><div style=\"width: 583px\" class=\"figure\"><div class=\"ttl\">Completed rhomboid flap with dressing</div><div class=\"cntnt\"><img style=\"width:563px; height:754px;\" src=\"images/SURG/117062_Completedrhmbdflpdrssing.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Image showing a completed rhomboid flap combined with placement of a negative pressure dressing at the superior portion of the natal cleft where an open wound remained. Some cases have such extensive disease that this approach may be needed; it may be difficult or impossible to create a flap large enough to cover all associated open wound. Refer to the related UpToDate topic for a description and video of this technique.</div><div id=\"graphicVersion\">Graphic 117062 Version 1.0</div></div></div>"},"117063":{"type":"graphic_picture","displayName":"Completed and healed Z-plasty flap","title":"Completed and healed Z-plasty flap","html":"<div class=\"graphic\"><div style=\"width: 585px\" class=\"figure\"><div class=\"ttl\">Completed and healed Z-plasty flap</div><div class=\"cntnt\"><img style=\"width:565px; height:755px;\" src=\"images/SURG/117063_CompletedhealdZplstyflp.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The photo depicts a healed Z-plasty excision of pilonidal disease with some of the sutures removed. The patient is prone. Refer to related UpToDate topics for the description of this technique.</div><div id=\"graphicVersion\">Graphic 117063 Version 1.0</div></div></div>"},"117076":{"type":"graphic_picture","displayName":"Soft mist inhaler PI","title":"Soft mist inhaler","html":"<div class=\"graphic\"><div style=\"width: 554px\" class=\"figure\"><div class=\"ttl\">Soft mist inhaler</div><div class=\"cntnt\"><img style=\"width:534px; height:704px;\" src=\"images/PI/117076_SoftmistinhalerPR.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Soft mist inhalers spray a mist of medicine that you breathe in when you press down on a button on the side of the inhaler.</div><div class=\"graphic_reference\">Reproduced with permission. Copyright &copy; 2018 Boehringer Ingelheim GmbH. All rights reserved.</div><div id=\"graphicVersion\">Graphic 117076 Version 1.0</div></div></div>"},"117079":{"type":"graphic_picture","displayName":"Raynaud phenomenon PI","title":"Raynaud phenomenon","html":"<div class=\"graphic\"><div style=\"width: 568px\" class=\"figure\"><div class=\"ttl\">Raynaud phenomenon</div><div class=\"cntnt\"><img style=\"width:548px; height:299px;\" src=\"images/PI/117079_RaynaudphenomenonPI.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">During a Raynaud attack, the fingers (or toes) become suddenly pale or white (panel A) as the blood vessels constrict. They might then turn a purple or blue color (panel B), which means there is less blood than normal flowing to the fingers. The thumb is often not affected.</div><div class=\"graphic_reference\">Courtesy of Fredrick M Wigley, MD.</div><div id=\"graphicVersion\">Graphic 117079 Version 1.0</div></div></div>"},"117086":{"type":"graphic_algorithm","displayName":"Mechanical thrombectomy for acute ischemic stroke","title":"Indications for mechanical thrombectomy to treat patients with acute ischemic stroke","html":"<div class=\"graphic\"><div style=\"width: 1188px\" class=\"figure\"><div class=\"ttl\">Indications for mechanical thrombectomy to treat patients with acute ischemic stroke</div><div class=\"cntnt\"><img style=\"width:1168px; height:561px;\" src=\"images/NEURO/117086_Thrombectmyactischmcstrk.gif\" alt=\"Image\"/></div><div class=\"graphic_footnotes\">IV: intravenous; tPA: tissue plasminogen activator; CTA: computed tomography angiography; MRA: magnetic resonance angiography; LAO: large artery occlusion; MT: mechanical thrombectomy; ASPECTS: Alberta Stroke Program Early CT Score; NIHSS: National Institutes of Health Stroke Scale; CT: computed tomography; MRI: magnetic resonance imaging; mRS: modified Rankin Scale; MCA: middle cerebral artery; ICA: internal carotid artery.<br />* Usually assessed with MRA or CTA, less often with digital subtraction angiography.<br />¶ There is intracranial arterial occlusion of the distal ICA, middle cerebral (M1/M2), or anterior cerebral (A1/A2) artery by CTA, MRA, or digital subtraction angiography.<br />Δ MT may be a treatment option for patients with acute ischemic stroke caused by occlusion of the basilar artery, vertebral arteries, or posterior cerebral arteries at expert stroke centers, but benefit is uncertain.</div><div id=\"graphicVersion\">Graphic 117086 Version 1.0</div></div></div>"},"117091":{"type":"graphic_picture","displayName":"Wire-reinforced endotracheal tube","title":"Wire-reinforced endotracheal tube","html":"<div class=\"graphic\"><div style=\"width: 481px\" class=\"figure\"><div class=\"ttl\">Wire-reinforced endotracheal tube</div><div class=\"cntnt\"><img style=\"width:461px; height:552px;\" src=\"images/ANEST/117091_Wirernfrcdendotrachealtb.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Wire-reinforced endotracheal tubes such as this one have an integrated spiral-wound reinforcing wire designed to reduce the risk of kinking, especially if the patient's head is flexed or extended.</div><div class=\"graphic_reference\">Shiley&trade; Oral/Nasal Endotracheal Tube &copy; 2018 Medtronic. All rights reserved. Used with the permission of Medtronic. Available at: <a href=\"http://www.medtronic.com/covidien/en-us/products/intubation/shiley-oral-nasal-endotracheal-tube-reinforced.html\" target=\"_blank\">http://www.medtronic.com/covidien/en-us/products/intubation/shiley-oral-nasal-endotracheal-tube-reinforced.html</a> (Accessed on March 6, 2018).</div><div id=\"graphicVersion\">Graphic 117091 Version 1.0</div></div></div>"},"117099":{"type":"graphic_figure","displayName":"Testosterone rx in unexplained anemia","title":"Association of testosterone versus placebo treatment in TTrials participants with unexplained anemia at baseline","html":"<div class=\"graphic\"><div style=\"width: 595px\" class=\"figure\"><div class=\"ttl\">Association of testosterone versus placebo treatment in TTrials participants with unexplained anemia at baseline</div><div class=\"cntnt\"><img style=\"width:575px; height:430px;\" src=\"images/ENDO/117099_Teststrnrxunexplndanemia.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Results in men with unexplained anemia, shown as dichotomous variables (ie, the percent of men who demonstrated an increase above baseline of 1 g/dL or more). The values are means±pointwise confidence intervals.</div><div class=\"graphic_footnotes\">TTrials: Testosterone Trials.</div><div class=\"graphic_reference\">Reproduced with permission from: Roy CN, Snyder PJ, Stephens-Shields AJ, et al. Association of testosterone levels with anemia in older men: A controlled clinical trial. JAMA Intern Med 2017; 177(4):480-90. Copyright © 2017 American Medical Association. All rights reserved.</div><div id=\"graphicVersion\">Graphic 117099 Version 1.0</div></div></div>"},"117100":{"type":"graphic_figure","displayName":"Testosterone rx effects on vBMD","title":"Effects of testosterone or placebo treatment for 12 months on volumetric bone mineral density","html":"<div class=\"graphic\"><div style=\"width: 602px\" class=\"figure\"><div class=\"ttl\">Effects of testosterone or placebo treatment for 12 months on volumetric bone mineral density</div><div class=\"cntnt\"><img style=\"width:582px; height:359px;\" src=\"images/ENDO/117100_TestosteronerxeffctsvBMD.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Bars indicate means, and error bars indicate standard deviations. The p values indicate the significance of the difference in change in percent vBMD from baseline to 12 months for men in the testosterone arm compared with the placebo arm.</div><div class=\"graphic_footnotes\">vBMD: volumetric bone mineral density.</div><div class=\"graphic_reference\">Reproduced with permission from: Snyder PJ, Kopperdahl DL, Stephens-Shields, AJ, et al. Effect of testosterone treatment on volumetric bone density and strength in older men with low testosterone: A controlled clinical trial. JAMA Intern Med 2017; 177(4):471-79. Copyright © 2017 American Medical Association. All rights reserved.</div><div id=\"graphicVersion\">Graphic 117100 Version 1.0</div></div></div>"},"117101":{"type":"graphic_table","displayName":"Goal BP according to risk for CVD and method of measuring BP","title":"Goal blood pressure according to baseline risk for cardiovascular disease and method of measuring blood pressure","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Goal blood pressure according to baseline risk for cardiovascular disease and method of measuring blood pressure</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"3\" width=\"33%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">&nbsp;</td> <td class=\"subtitle1\">Routine/conventional office blood pressure (manual measurement with stethoscope or oscillometric device)*</td> <td class=\"subtitle1\">Unattended AOBPM, daytime ABPM, or home blood pressure<sup>&#182;</sup></td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"3\">Higher-risk population<sup>&#916;</sup></td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\"> <ul> <li>Known ASCVD<sup>&#9674;</sup> </li> <li>Heart failure </li> <li>Diabetes mellitus </li> <li>Chronic kidney disease </li> <li>Age &#8805;65 years<sup>&#167;</sup> </li> <li>Calculated 10-year risk of ASCVD event &#8805;10%<sup>&#165;</sup> </li> </ul> </td> <td class=\"centered\">125 to 130/&#60;80</td> <td class=\"centered\">120 to 125/&#60;80</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"3\">Lower-risk<sup>&#135;</sup></td> </tr> <tr> <td class=\"indent1\"> <ul> <li>None of the above risk factors </li> </ul> </td> <td class=\"centered\">130 to 139/&#60;90</td> <td class=\"centered\">125 to 135/&#60;90</td> </tr> </tbody></table></div><div class=\"graphic_lgnd\"><ul>&#xD;&#xA;    <li>All target ranges presented above are in mmHg.</li>&#xD;&#xA;    <li>On average, blood pressure readings are 5 to 10 mmHg lower with digital, unattended, or out-of-office methods of measurement (ie, AOBPM, daytime ABPM, home blood pressure) than with routine/standard methods of office measurement (ie, manual auscultatory or oscillometric measurement), presumably due to the \"white coat effect.\" However, it is critical to realize that this average difference in blood pressures according to the methodology of measurement applies to the population and not the individual. Some patients do not experience a white coat effect, and, therefore, there is some uncertainty in setting goals that are specific to the method of measurement.</li>&#xD;&#xA;    <li>When treating to these goals, a patient may (inadvertently) attain a blood pressure below the given target. Provided the patient does not develop symptoms, side effects, or adverse events as a result of the treatment regimen, then reducing or withdrawing antihypertensive medications is unnecessary.</li>&#xD;&#xA;    <li>Less aggressive goals than those presented in the table may be appropriate for specific groups of patients, including those with postural hypotension, the frail older adult patient, and those with side effects to multiple antihypertensive medications.</li>&#xD;&#xA;  </ul></div><div class=\"graphic_footnotes\">AOBPM: automated oscillometric blood pressure; ABPM: ambulatory blood pressure monitoring; ASCVD: atherosclerotic cardiovascular disease; ACC/AHA: American College of Cardiology/American Heart Association.<br />* Office blood pressure must be performed adequately in order to use such measurements to manage patients. Critical to an adequate office assessment of blood pressure are proper patient positioning (eg, seated in a chair, feet flat on the floor, arm supported, remove clothing covering the location of cuff placement) and proper technique (eg, calibrated device, proper-sized cuff). The average of multiple measurements should be used for management. Refer to UpToDate topics on measurement of blood pressure. Office readings should not be used to manage blood pressure unless it is performed adequately.<br />¶ Home blood pressure, like office blood pressure, must be performed adequately in order for the measurements to be used to manage patients. First, the accuracy of the home blood pressure device must be verified in the clinician's office. Second, the clinician should verify that the cuff and bladder that the patient will use are the appropriate size. Third, patients should measure their pressure after several minutes of rest and while seated in a chair (back supported and feet flat on the floor) with their arm supported (eg, resting on a table). Fourth, the blood pressure should be measured at different times per day and over multiple days. The average value of these multiple measurements is used for management. Home blood pressure readings should not be used to manage blood pressure unless it is performed adequately and in conjunction with office blood pressure or ambulatory blood pressure.<br />Δ The level of evidence supporting the lower goal in higher-risk individuals is stronger for some risk groups (eg, patients with known coronary heart disease, patients with a calculated 10-year risk ≥15%, chronic kidney disease) than for other risk groups (eg, diabetic patients, patients with a prior stroke). Refer to UpToDate topics on goal blood pressure for a discussion of the evidence.<br /><FONT class=lozenge>◊</FONT> Prior history of coronary heart disease (acute coronary syndrome or stable angina), prior stroke or transient ischemic attack, prior history of peripheral artery disease.<br />§ In older adults with severe frailty, dementia, and/or a limited life expectancy, or in patients who are nonambulatory or institutionalized (eg, reside in a skilled nursing facility), we individualize goals and share decision-making with the patient, relatives, and caretakers, rather than targeting one of the blood pressure goals in the table.<br />¥ The 2013 ACC/AHA cardiovascular risk assessment calculator should be used to estimate 10-year cardiovascular disease risk.<br />‡ In the large subgroup of patients who have an initial (pretreatment) blood pressure ≥140/≥90 mmHg, but who do not have any of the other listed cardiovascular risk factors, some experts would set a more aggressive blood pressure goal of &lt;130/&lt;80 mmHg rather than those presented in the table. This more aggressive goal would likely reduce the chance of developing severe hypertension and ultimately lower the relative risk of cardiovascular events in these lower-risk patients over the long-term. However, the absolute benefit of more aggressive blood pressure lowering in these patients is comparatively small, and a lower goal would require more intensive pharmacologic therapy and corresponding side effects.</div><div id=\"graphicVersion\">Graphic 117101 Version 1.0</div></div></div>"},"117103":{"type":"graphic_diagnosticimage","displayName":"Evans index","title":"Evans index","html":"<div class=\"graphic\"><div style=\"width: 578px\" class=\"figure\"><div class=\"ttl\">Evans index</div><div class=\"cntnt\"><img style=\"width:558px; height:657px;\" src=\"images/NEURO/117103_Evansindex.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Axial CT image showing hydrocephalus and calculation of the Evans index. If the frontal horn measurement (arrow) as a ratio of the inner table of the skull (dashed arrow) is greater than 0.31, then the ventricles are enlarged.</div><div class=\"graphic_footnotes\">CT: computed tomography.</div><div class=\"graphic_reference\">Courtesy of Neill Graff-Radford, MBBCh, FRCP.</div><div id=\"graphicVersion\">Graphic 117103 Version 1.0</div></div></div>"},"117105":{"type":"graphic_diagnosticimage","displayName":"Axial MRI showing typical findings of idiopathic NPH","title":"Axial MRI showing typical findings of idiopathic NPH","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Axial MRI showing typical findings of idiopathic NPH</div><div class=\"cntnt\"><img style=\"width:351px; height:351px;\" src=\"images/NEURO/117105_AxlMRIshtypfdidptcNPH.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Axial MRI FLAIR sequences demonstrating features of NPH including the features of DESH: enlarged ventricles (arrows), enlarged Sylvian fissures (dashed arrows), entrapped fluid in sulci (thick arrows; not to be mistaken for atrophy), and high tight sulci (arrowhead).</div><div class=\"graphic_footnotes\">MRI: magnetic resonance imaging; NPH: normal pressure hydrocephalus; FLAIR: fluid-attenuated inversion recovery; DESH: disproportionately enlarged subarachnoid space hydrocephalus.</div><div class=\"graphic_reference\">Courtesy of Neill Graff-Radford, MBBCh, FRCP.</div><div id=\"graphicVersion\">Graphic 117105 Version 1.0</div></div></div>"},"117111":{"type":"graphic_table","displayName":"Checklist for discharge planning for infants admitted to NICU","title":"Checklist for discharge planning for infants admitted to the neonatal intensive care unit (NICU)","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Checklist for discharge planning for infants admitted to the neonatal intensive care unit (NICU)</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1_single\">Neonatal planning</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\"> <ol class=\"numbers_to_nine\"> <li>Neonatal status and readiness: <ol style=\"list-style-type: lower-alpha;\"> <li>Able to maintain temperature in open crib with normal ambient temperature </li> <li>Adequate cardiorespiratory control without episodes of apnea and bradycardia </li> <li>Adequate intake to promote appropriate growth and demonstrated a consistent pattern of appropriate weight prior to discharge </li> <li>Able to sleep in a flat and supine position </li> </ol> </li> <li>Completion of routine screening including: <ol style=\"list-style-type: lower-alpha;\"> <li>Metabolic and genetic disorders </li> <li>Retinopathy of prematurity for infants with gestational age &#60;30 weeks </li> <li>Hearing screening using auditory brainstem response </li> <li>Other screening tests based on clinical settings may include brain imaging and laboratory studies (eg, complete blood count or alkaline phosphatase)</li> </ol> </li> <li>Routine immunization based on chronological age consistent with the schedule and dose recommended for normal full-term infants </li> <li>Passing car seat/bed test </li> <li>Identify specialized needs for individual patients, including medication, formula, medical equipment, and in cases of incurable terminal conditions, hospice care </li> </ol> </td> </tr> <tr> <td class=\"subtitle1_single\">Family planning</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\"> <ol class=\"numbers_to_nine\"> <li>Parental education and readiness: <ol style=\"list-style-type: lower-alpha;\"> <li>Demonstrate competency in the daily care of their infant </li> <li>Demonstrate knowledge of normal behavior of their infant and ability to recognize signs and symptoms of illnesses that require medical consultation </li> <li>Understand safety (eg, sleep position and environment) and coping measures for the care of their infant </li> </ol> </li> <li>Home environment preparation: <ol style=\"list-style-type: lower-alpha;\"> <li>Obtain the necessary supplies and equipment needed for the daily care of their infant </li> <li>Evaluation of social and financial needs that may require additional supports, and if needed, appropriate referrals are made </li> </ol> </li> </ol> </td> </tr> <tr> <td class=\"subtitle1_single\">Transition planning and post-discharge care</td> </tr> <tr> <td class=\"indent1\"> <ol class=\"numbers_to_nine\"> <li>Primary care provider: <ol style=\"list-style-type: lower-alpha;\"> <li>An appointment with a primary care provider (PCP) with expertise in the care of graduates from the NICU is scheduled within 48 to 72 hours after discharge </li> <li>Prior communication between the NICU team and PCP has occurred with review of the infant's NICU course and a summary of ongoing care issues </li> </ol> </li> <li>Specialty follow-up: <ol style=\"list-style-type: lower-alpha;\"> <li>If appropriate, appointments scheduled for post-discharge follow-up with subspecialty services </li> </ol> </li> <li>Community services: <ol style=\"list-style-type: lower-alpha;\"> <li>If appropriate, follow-up with community services </li> </ol> </li> </ol> </td> </tr> </tbody></table></div><div id=\"graphicVersion\">Graphic 117111 Version 1.0</div></div></div>"},"117123":{"type":"graphic_picture","displayName":"RBCs transmission EM","title":"Transmission electron micrograph showing biconcave disc shape of normal red blood cells","html":"<div class=\"graphic\"><div style=\"width: 696px\" class=\"figure\"><div class=\"ttl\">Transmission electron micrograph showing biconcave disc shape of normal red blood cells</div><div class=\"cntnt\"><img style=\"width:676px; height:753px;\" src=\"images/HEME/117123_RBCs.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The biconcave disc shape of the RBC is determined by the ratio of membrane&nbsp;surface area&nbsp;to internal cytoplasmic volume, referred to as the surface area-to-volume ratio (SA/V). The membrane surface area&nbsp;in turn depends on a highly regulated&nbsp;array of membrane phospholipids in a lipid bilayer and an underlying cytoskeletal network, which are linked via vertical associations with integral membrane proteins.&nbsp;Refer to UpToDate discussions of the RBC membrane for details.</div><div class=\"graphic_footnotes\">RBCs: red blood cells; EM: electron micrograph</div><div class=\"graphic_reference\">Courtesy of Mohandas Narla, DSc.</div><div id=\"graphicVersion\">Graphic 117123 Version 1.0</div></div></div>"},"117141":{"type":"graphic_table","displayName":"Breast carcinoma TNM pathologic prognostic stage groups 2017","title":"Breast carcinoma TNM pathologic prognostic stage groups AJCC UICC 2017","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Breast carcinoma TNM pathologic prognostic stage groups AJCC UICC 2017</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"6\" width=\"16%\"></colgroup> <tbody> <tr> <td class=\"subtitle1_left\">When TNM is...</td> <td class=\"subtitle1_left\">And grade is...</td> <td class=\"subtitle1_left\">And HER2 status is...</td> <td class=\"subtitle1_left\">And ER status is...</td> <td class=\"subtitle1_left\">And PR status is...</td> <td class=\"subtitle1_left\">Then the pathological prognostic stage group is...</td> </tr> <tr class=\"divider_top divider_bottom\"> <td class=\"indent1\">Tis N0 M0</td> <td>Any</td> <td>Any</td> <td>Any</td> <td>Any</td> <td>0</td> </tr> <tr> <td class=\"indent1 divider_bottom\" rowspan=\"8\"> <p>T1* N0 M0</p> <p>T0 N1mi M0</p> T1* N1mi M0</td> <td class=\"divider_bottom\" rowspan=\"8\">G1</td> <td class=\"divider_bottom\" rowspan=\"4\">Positive</td> <td rowspan=\"2\">Positive</td> <td>Positive</td> <td>IA</td> </tr> <tr> <td>Negative</td> <td>IA</td> </tr> <tr> <td class=\"divider_bottom\" rowspan=\"2\">Negative</td> <td>Positive</td> <td>IA</td> </tr> <tr class=\"divider_bottom\"> <td>Negative</td> <td>IA</td> </tr> <tr> <td class=\"divider_bottom\" rowspan=\"4\">Negative</td> <td rowspan=\"2\">Positive</td> <td>Positive</td> <td>IA</td> </tr> <tr> <td>Negative</td> <td>IA</td> </tr> <tr> <td class=\"divider_bottom\" rowspan=\"2\">Negative</td> <td>Positive</td> <td>IA</td> </tr> <tr class=\"divider_bottom\"> <td>Negative</td> <td>IA</td> </tr> <tr> <td class=\"indent1 divider_bottom\" rowspan=\"8\"> <p>T1* N0 M0</p> <p>T0 N1mi M0</p> T1* N1mi M0</td> <td class=\"divider_bottom\" rowspan=\"8\">G2</td> <td class=\"divider_bottom\" rowspan=\"4\">Positive</td> <td rowspan=\"2\">Positive</td> <td>Positive</td> <td>IA</td> </tr> <t /> <tr> <td>Negative</td> <td>IA</td> </tr> <tr> <td class=\"divider_bottom\" rowspan=\"2\">Negative</td> <td>Positive</td> <td>IA</td> </tr> <tr class=\"divider_bottom\"> <td>Negative</td> <td>IA</td> </tr> <tr> <td class=\"divider_bottom\" rowspan=\"4\">Negative</td> <td rowspan=\"2\">Positive</td> <td>Positive</td> <td>IA</td> </tr> <tr> <td>Negative</td> <td>IA</td> </tr> <tr> <td class=\"divider_bottom\" rowspan=\"2\">Negative</td> <td>Positive</td> <td>IA</td> </tr> <tr class=\"divider_bottom\"> <td>Negative</td> <td>IB</td> </tr> <tr> <td class=\"indent1 divider_bottom\" rowspan=\"8\"> <p>T1* N0 M0</p> <p>T0 N1mi M0</p> T1* N1mi M0</td> <td class=\"divider_bottom\" rowspan=\"8\">G3</td> <td class=\"divider_bottom\" rowspan=\"4\">Positive</td> <td rowspan=\"2\">Positive</td> <td>Positive</td> <td>IA</td> </tr> <tr> <td>Negative</td> <td>IA</td> </tr> <tr> <td class=\"divider_bottom\" rowspan=\"2\">Negative</td> <td>Positive</td> <td>IA</td> </tr> <tr class=\"divider_bottom\"> <td>Negative</td> <td>IA</td> </tr> <tr> <td class=\"divider_bottom\" rowspan=\"4\">Negative</td> <td rowspan=\"2\">Positive</td> <td>Positive</td> <td>IA</td> </tr> <tr> <td>Negative</td> <td>IA</td> </tr> <tr> <td class=\"divider_bottom\" rowspan=\"2\">Negative</td> <td>Positive</td> <td>IA</td> </tr> <tr class=\"divider_bottom\"> <td>Negative</td> <td>IB</td> </tr> <tr> <td class=\"indent1 divider_bottom\" rowspan=\"8\"> <p>T0 N1<sup>&#182;</sup> M0</p> <p>T1* N1<sup>&#182;</sup> M0</p> T2 N0 M0</td> <td class=\"divider_bottom\" rowspan=\"8\">G1</td> <td class=\"divider_bottom\" rowspan=\"4\">Positive</td> <td rowspan=\"2\">Positive</td> <td>Positive</td> <td>IA</td> </tr> <tr> <td>Negative</td> <td>IB</td> </tr> <tr> <td class=\"divider_bottom\" rowspan=\"2\">Negative</td> <td>Positive</td> <td>IB</td> </tr> <tr class=\"divider_bottom\"> <td>Negative</td> <td>IIA</td> </tr> <tr> <td class=\"divider_bottom\" rowspan=\"4\">Negative</td> <td rowspan=\"2\">Positive</td> <td>Positive</td> <td>IA</td> </tr> <tr> <td>Negative</td> <td>IB</td> </tr> <tr> <td class=\"divider_bottom\" rowspan=\"2\">Negative</td> <td>Positive</td> <td>IB</td> </tr> <tr class=\"divider_bottom\"> <td>Negative</td> <td>IIA</td> </tr> <tr> <td class=\"indent1 divider_bottom\" rowspan=\"8\"> <p>T0 N1<sup>&#182;</sup> M0</p> <p>T1* N1<sup>&#182;</sup> M0</p> T2 N0 M0</td> <td class=\"divider_bottom\" rowspan=\"8\">G2</td> <td class=\"divider_bottom\" rowspan=\"4\">Positive</td> <td rowspan=\"2\">Positive</td> <td>Positive</td> <td>IA</td> </tr> <t /> <tr> <td>Negative</td> <td>IB</td> </tr> <tr> <td class=\"divider_bottom\" rowspan=\"2\">Negative</td> <td>Positive</td> <td>IB</td> </tr> <tr class=\"divider_bottom\"> <td>Negative</td> <td>IIA</td> </tr> <tr> <td class=\"divider_bottom\" rowspan=\"4\">Negative</td> <td rowspan=\"2\">Positive</td> <td>Positive</td> <td>IA</td> </tr> <tr> <td>Negative</td> <td>IIA</td> </tr> <tr> <td class=\"divider_bottom\" rowspan=\"2\">Negative</td> <td>Positive</td> <td>IIA</td> </tr> <tr class=\"divider_bottom\"> <td>Negative</td> <td>IIA</td> </tr> <tr> <td class=\"indent1 divider_bottom\" rowspan=\"8\"> <p>T0 N1<sup>&#182;</sup> M0</p> <p>T1* N1<sup>&#182;</sup> M0</p> T2 N0 M0</td> <td class=\"divider_bottom\" rowspan=\"8\">G3</td> <td class=\"divider_bottom\" rowspan=\"4\">Positive</td> <td rowspan=\"2\">Positive</td> <td>Positive</td> <td>IA</td> </tr> <tr> <td>Negative</td> <td>IIA</td> </tr> <tr> <td class=\"divider_bottom\" rowspan=\"2\">Negative</td> <td>Positive</td> <td>IIA</td> </tr> <tr class=\"divider_bottom\"> <td>Negative</td> <td>IIA</td> </tr> <tr> <td class=\"divider_bottom\" rowspan=\"4\">Negative</td> <td rowspan=\"2\">Positive</td> <td>Positive</td> <td>IB</td> </tr> <tr> <td>Negative</td> <td>IIA</td> </tr> <tr> <td class=\"divider_bottom\" rowspan=\"2\">Negative</td> <td>Positive</td> <td>IIA</td> </tr> <tr class=\"divider_bottom\"> <td>Negative</td> <td>IIA</td> </tr> <tr> <td class=\"indent1 divider_bottom\" rowspan=\"8\"> <p>T2 N1<sup>&#916;</sup> M0</p> T3 N0 M0</td> <td class=\"divider_bottom\" rowspan=\"8\">G1</td> <td class=\"divider_bottom\" rowspan=\"4\">Positive</td> <td rowspan=\"2\">Positive</td> <td>Positive</td> <td>IA</td> </tr> <tr> <td>Negative</td> <td>IIB</td> </tr> <tr> <td class=\"divider_bottom\" rowspan=\"2\">Negative</td> <td>Positive</td> <td>IIB</td> </tr> <tr class=\"divider_bottom\"> <td>Negative</td> <td>IIB</td> </tr> <tr> <td class=\"divider_bottom\" rowspan=\"4\">Negative</td> <td rowspan=\"2\">Positive</td> <td>Positive</td> <td>IA</td> </tr> <tr> <td>Negative</td> <td>IIB</td> </tr> <tr> <td class=\"divider_bottom\" rowspan=\"2\">Negative</td> <td>Positive</td> <td>IIB</td> </tr> <tr class=\"divider_bottom\"> <td>Negative</td> <td>IIB</td> </tr> <tr> <td class=\"indent1 divider_bottom\" rowspan=\"8\"> <p>T2 N1<sup>&#916;</sup> M0</p> T3 N0 M0</td> <td class=\"divider_bottom\" rowspan=\"8\">G2</td> <td class=\"divider_bottom\" rowspan=\"4\">Positive</td> <td rowspan=\"2\">Positive</td> <td>Positive</td> <td>IB</td> </tr> <t /> <tr> <td>Negative</td> <td>IIB</td> </tr> <tr> <td class=\"divider_bottom\" rowspan=\"2\">Negative</td> <td>Positive</td> <td>IIB</td> </tr> <tr class=\"divider_bottom\"> <td>Negative</td> <td>IIB</td> </tr> <tr> <td class=\"divider_bottom\" rowspan=\"4\">Negative</td> <td rowspan=\"2\">Positive</td> <td>Positive</td> <td>IB</td> </tr> <tr> <td>Negative</td> <td>IIB</td> </tr> <tr> <td class=\"divider_bottom\" rowspan=\"2\">Negative</td> <td>Positive</td> <td>IIB</td> </tr> <tr class=\"divider_bottom\"> <td>Negative</td> <td>IIB</td> </tr> <tr> <td class=\"indent1 divider_bottom\" rowspan=\"8\"> <p>T2 N1<sup>&#916;</sup> M0</p> T3 N0 M0</td> <td class=\"divider_bottom\" rowspan=\"8\">G3</td> <td class=\"divider_bottom\" rowspan=\"4\">Positive</td> <td rowspan=\"2\">Positive</td> <td>Positive</td> <td>IB</td> </tr> <tr> <td>Negative</td> <td>IIB</td> </tr> <tr> <td class=\"divider_bottom\" rowspan=\"2\">Negative</td> <td>Positive</td> <td>IIB</td> </tr> <tr class=\"divider_bottom\"> <td>Negative</td> <td>IIB</td> </tr> <tr> <td class=\"divider_bottom\" rowspan=\"4\">Negative</td> <td rowspan=\"2\">Positive</td> <td>Positive</td> <td>IIA</td> </tr> <tr> <td>Negative</td> <td>IIB</td> </tr> <tr> <td class=\"divider_bottom\" rowspan=\"2\">Negative</td> <td>Positive</td> <td>IIB</td> </tr> <tr class=\"divider_bottom\"> <td>Negative</td> <td>IIIA</td> </tr> <tr> <td class=\"indent1 divider_bottom\" rowspan=\"8\"> <p>T0 N2 M0</p> <p>T1* N2 M0</p> <p>T2 N2 M0</p> <p>T3 N1<sup>&#916;</sup> M0</p> T3 N2 M0</td> <td class=\"divider_bottom\" rowspan=\"8\">G1</td> <td class=\"divider_bottom\" rowspan=\"4\">Positive</td> <td rowspan=\"2\">Positive</td> <td>Positive</td> <td>IB</td> </tr> <tr> <td>Negative</td> <td>IIIA</td> </tr> <tr> <td class=\"divider_bottom\" rowspan=\"2\">Negative</td> <td>Positive</td> <td>IIIA</td> </tr> <tr class=\"divider_bottom\"> <td>Negative</td> <td>IIIA</td> </tr> <tr> <td class=\"divider_bottom\" rowspan=\"4\">Negative</td> <td rowspan=\"2\">Positive</td> <td>Positive</td> <td>IB</td> </tr> <tr> <td>Negative</td> <td>IIIA</td> </tr> <tr> <td class=\"divider_bottom\" rowspan=\"2\">Negative</td> <td>Positive</td> <td>IIIA</td> </tr> <tr class=\"divider_bottom\"> <td>Negative</td> <td>IIIA</td> </tr> <tr> <td class=\"indent1 divider_bottom\" rowspan=\"8\"> <p>T0 N2 M0</p> <p>T1* N2 M0</p> <p>T2 N2 M0</p> <p>T3 N1<sup>&#916;</sup> M0</p> T3 N2 M0</td> <td class=\"divider_bottom\" rowspan=\"8\">G2</td> <td class=\"divider_bottom\" rowspan=\"4\">Positive</td> <td rowspan=\"2\">Positive</td> <td>Positive</td> <td>IB</td> </tr> <t /> <tr> <td>Negative</td> <td>IIIA</td> </tr> <tr> <td class=\"divider_bottom\" rowspan=\"2\">Negative</td> <td>Positive</td> <td>IIIA</td> </tr> <tr class=\"divider_bottom\"> <td>Negative</td> <td>IIIA</td> </tr> <tr> <td class=\"divider_bottom\" rowspan=\"4\">Negative</td> <td rowspan=\"2\">Positive</td> <td>Positive</td> <td>IB</td> </tr> <tr> <td>Negative</td> <td>IIIA</td> </tr> <tr> <td class=\"divider_bottom\" rowspan=\"2\">Negative</td> <td>Positive</td> <td>IIIA</td> </tr> <tr class=\"divider_bottom\"> <td>Negative</td> <td>IIIB</td> </tr> <tr> <td class=\"indent1 divider_bottom\" rowspan=\"8\"> <p>T0 N2 M0</p> <p>T1* N2 M0</p> <p>T2 N2 M0</p> <p>T3 N1<sup>&#916;</sup> M0</p> T3 N2 M0</td> <td class=\"divider_bottom\" rowspan=\"8\">G3</td> <td class=\"divider_bottom\" rowspan=\"4\">Positive</td> <td rowspan=\"2\">Positive</td> <td>Positive</td> <td>IIA</td> </tr> <tr> <td>Negative</td> <td>IIIA</td> </tr> <tr> <td class=\"divider_bottom\" rowspan=\"2\">Negative</td> <td>Positive</td> <td>IIIA</td> </tr> <tr class=\"divider_bottom\"> <td>Negative</td> <td>IIIA</td> </tr> <tr> <td class=\"divider_bottom\" rowspan=\"4\">Negative</td> <td rowspan=\"2\">Positive</td> <td>Positive</td> <td>IIB</td> </tr> <tr> <td>Negative</td> <td>IIIA</td> </tr> <tr> <td class=\"divider_bottom\" rowspan=\"2\">Negative</td> <td>Positive</td> <td>IIIA</td> </tr> <tr class=\"divider_bottom\"> <td>Negative</td> <td>IIIC</td> </tr> <tr> <td class=\"indent1 divider_bottom\" rowspan=\"8\"> <p>T4 N0 M0</p> <p>T4 N1<sup>&#916;</sup> M0</p> <p>T4 N2 M0</p> Any T N3 M0</td> <td class=\"divider_bottom\" rowspan=\"8\">G1</td> <td class=\"divider_bottom\" rowspan=\"4\">Positive</td> <td rowspan=\"2\">Positive</td> <td>Positive</td> <td>IIIA</td> </tr> <tr> <td>Negative</td> <td>IIIB</td> </tr> <tr> <td class=\"divider_bottom\" rowspan=\"2\">Negative</td> <td>Positive</td> <td>IIIB</td> </tr> <tr class=\"divider_bottom\"> <td>Negative</td> <td>IIIB</td> </tr> <tr> <td class=\"divider_bottom\" rowspan=\"4\">Negative</td> <td rowspan=\"2\">Positive</td> <td>Positive</td> <td>IIIA</td> </tr> <tr> <td>Negative</td> <td>IIIB</td> </tr> <tr> <td class=\"divider_bottom\" rowspan=\"2\">Negative</td> <td>Positive</td> <td>IIIB</td> </tr> <tr class=\"divider_bottom\"> <td>Negative</td> <td>IIIB</td> </tr> <tr> <td class=\"indent1 divider_bottom\" rowspan=\"8\"> <p>T4 N0 M0</p> <p>T4 N1<sup>&#916;</sup> M0</p> <p>T4 N2 M0</p> Any T N3 M0</td> <td class=\"divider_bottom\" rowspan=\"8\">G2</td> <td class=\"divider_bottom\" rowspan=\"4\">Positive</td> <td rowspan=\"2\">Positive</td> <td>Positive</td> <td>IIIA</td> </tr> <t /> <tr> <td>Negative</td> <td>IIIB</td> </tr> <tr> <td class=\"divider_bottom\" rowspan=\"2\">Negative</td> <td>Positive</td> <td>IIIB</td> </tr> <tr class=\"divider_bottom\"> <td>Negative</td> <td>IIIB</td> </tr> <tr> <td class=\"divider_bottom\" rowspan=\"4\">Negative</td> <td rowspan=\"2\">Positive</td> <td>Positive</td> <td>IIIA</td> </tr> <tr> <td>Negative</td> <td>IIIB</td> </tr> <tr> <td class=\"divider_bottom\" rowspan=\"2\">Negative</td> <td>Positive</td> <td>IIIB</td> </tr> <tr class=\"divider_bottom\"> <td>Negative</td> <td>IIIC</td> </tr> <tr> <td class=\"indent1 divider_bottom\" rowspan=\"8\"> <p>T4 N0 M0</p> <p>T4 N1<sup>&#916;</sup> M0</p> <p>T4 N2 M0</p> Any T N3 M0</td> <td class=\"divider_bottom\" rowspan=\"8\">G3</td> <td class=\"divider_bottom\" rowspan=\"4\">Positive</td> <td rowspan=\"2\">Positive</td> <td>Positive</td> <td>IIIB</td> </tr> <tr> <td>Negative</td> <td>IIIB</td> </tr> <tr> <td class=\"divider_bottom\" rowspan=\"2\">Negative</td> <td>Positive</td> <td>IIIB</td> </tr> <tr class=\"divider_bottom\"> <td>Negative</td> <td>IIIB</td> </tr> <tr> <td class=\"divider_bottom\" rowspan=\"4\">Negative</td> <td rowspan=\"2\">Positive</td> <td>Positive</td> <td>IIIB</td> </tr> <tr> <td>Negative</td> <td>IIIC</td> </tr> <tr> <td class=\"divider_bottom\" rowspan=\"2\">Negative</td> <td>Positive</td> <td>IIIC</td> </tr> <tr class=\"divider_bottom\"> <td>Negative</td> <td>IIIC</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Any T Any N M1</td> <td>Any</td> <td>Any</td> <td>Any</td> <td>Any</td> <td>IV</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1 divider_bottom\" colspan=\"6\"><em>NOTES:</em> <ol> <li>For cases with lymph node involvement with no evidence of primary tumor (eg, T0 N1, etc) or with breast ductal carcinoma <em>in situ</em> (eg, Tis N1, etc), the grade, HER2, ER, and PR information from the tumor in the lymph node should be used for assigning stage group. </li> <li>For cases where HER2 is determined to be \"equivocal\" by ISH (FISH or CISH) testing under the 2013 ASCO/CAP HER2 testing guidelines, the HER2 \"negative\" category should be used for staging in the pathological prognostic stage group table.</li> <li>The prognostic value of these prognostic stage groups is based on populations of persons with breast cancer that have been offered and mostly treated with appropriate endocrine and/or systemic chemotherapy (including anti-HER2 therapy). </li> </ol> </td> </tr> <tr class=\"divider_top\"> <td class=\"small divider_bottom\" colspan=\"6\">&nbsp;</td> </tr> <tr class=\"divider_top\"> <td class=\"subtitle1_left\" colspan=\"6\">Genomic profile for pathologic prognostic staging</td> </tr> <tr class=\"divider_bottom\"> <td class=\"subtitle2_left\" colspan=\"6\">When OncotypeDx score is less than 11...</td> </tr> <tr class=\"highlight_gray_text divider_bottom\"> <td class=\"indent1\"><strong>When TNM is...</strong></td> <td><strong>And grade is...</strong></td> <td><strong>And HER2 status is...</strong></td> <td><strong>And ER status is...</strong></td> <td><strong>And PR status is...</strong></td> <td><strong>Then the pathological prognostic stage group is...</strong></td> </tr> <tr> <td class=\"indent2\"> <p>T1 N0 M0</p> T2 N0 M0</td> <td>Any</td> <td>Negative</td> <td>Positive</td> <td>Any</td> <td>IA</td> </tr> <tr> <td class=\"indent2\" colspan=\"6\"><em>NOTES:</em> <ol> <li>Obtaining genomic profiles is NOT required for assigning pathological prognostic stage. However genomic profiles may be performed for use in determining appropriate treatment. If the OncotypeDx test is performed in cases with a T1N0M0 or T2N0M0 cancer that is HER2-negative and ER-positive, and the recurrence score is less than 11, the case should be assigned pathological prognostic stage group IA. </li> <li>If OncotypeDx is not performed, or if it is performed and the OncotypeDx score is not available, or is 11 or greater for patients with T1-2 N0 M0 HER2-negative, ER-positive cancer, then the prognostic stage group is assigned based on the anatomic and biomarker categories shown above. </li> <li>OncotypeDx is the only multigene panel included to classify pathologic prognostic stage because prospective level I data supports this use for patients with a score less than 11. Future updates to the staging system may include results from other multigene panels to assign cohorts of patients to prognostic stage groups based on the then available evidence. Inclusion or exclusion in this staging table of a genomic profile assay is not an endorsement of any specific assay and should not limit appropriate clinical use of any genomic profile assay based on evidence available at the time of treatment. </li> </ol> </td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">TNM: tumor, node, metastasis; AJCC: American Joint Committee on Cancer; UICC: Union for International Cancer Control.<br />* T1 includes T1mi.<br />&para; N1 does not include N1mi. T1 N1mi M0 and T0 N1mi M0 cancers are included for prognostic staging with T1 N0 M0 cancers of the same prognostic factor status.<br />&Delta; N1 includes N1mi. T2, T3, and T4 cancers and N1mi are included for prognostic staging with T2 N1, T3 N1, and T4 N1, respectively.</div><div class=\"graphic_reference\">Used with permission of the American College of Surgeons, Chicago, Illinois. The original source for this information is the AJCC Cancer Staging Manual, Eighth Edition (2017) published by Springer International Publishing. Corrected at 3rd printing, 2017.</div><div id=\"graphicVersion\">Graphic 117141 Version 1.0</div></div></div>"},"117172":{"type":"graphic_algorithm","displayName":"Approach to macrocephaly in children","title":"Our approach to the evaluation of the child with macrocephaly","html":"<div class=\"graphic\"><div style=\"width: 863px\" class=\"figure\"><div class=\"ttl\">Our approach to the evaluation of the child with macrocephaly</div><div class=\"cntnt\"><img style=\"width:843px; height:1015px;\" src=\"images/PEDS/117172_Approachmacrocephalychild.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This algorithm is intended for use in conjunction with the UpToDate topic on macrocephaly in children. The baseline evaluation includes history and physical examination with particular attention to: &#xD;&#xA;<UL class=decimal_heading>&#xD;&#xA;<LI>History: CNS trauma or infection; associated neurologic symptoms (eg, headache, vomiting, ataxia, altered mental status)</LI>&#xD;&#xA;<LI>Physical examination: Delayed development, bulging fontanelle (in infant), papilledema, meningismus, or other abnormal neurologic findings; neurologic or cutaneous findings suggestive of multisystem disease or syndrome</LI>&#xD;&#xA;<LI>Family history: Macrocephaly, multisystem disease or syndrome</LI>&#xD;&#xA;<LI>Measurement of parents' OFC</LI></UL></div><div class=\"graphic_footnotes\">OFC: occipitofrontal circumference; ICP: intracranial pressure; CNS: central nervous system; SD: standard deviation; MRI: magnetic resonance imaging.<br />* Progressive enlargement is defined by crossing ≥1 major percentile line (eg, 10<SUP>th</SUP>, 25<SUP>th</SUP>, 50<SUP>th</SUP>, 75<SUP>th</SUP>, 90<SUP>th</SUP>) between health supervision visits.<br />¶ Refer to UpToDate content on increased intracranial pressure, meningitis, and encephalitis in children for details.<br />Δ Refer to UpToDate content on macrocephaly in children for details.<br /><FONT class=lozenge>◊</FONT> Refer to UpToDate content on developmental surveillance and screening. Children with macrocephaly and developmental delay or neurologic findings may warrant neurology referral or consultation in addition to neuroimaging.<br />§ The laboratory evaluation varies with the clinical manifestations. Refer to UpToDate content on inborn errors of metabolism for details of evaluation.</div><div id=\"graphicVersion\">Graphic 117172 Version 1.0</div></div></div>"},"117179":{"type":"graphic_algorithm","displayName":"Disposition of adult patient isolated rib fracture or fractures","title":"Disposition of adult patient with isolated rib fracture or fractures","html":"<div class=\"graphic\"><div style=\"width: 538px\" class=\"figure\"><div class=\"ttl\">Disposition of adult patient with isolated rib fracture or fractures</div><div class=\"cntnt\"><img style=\"width:518px; height:395px;\" src=\"images/EM/117179_Adltisoltribfrxtrfrxtrs.gif\" alt=\"Image\"/></div><div class=\"graphic_footnotes\">ICU: intensive care unit; IS: incentive spirometry; SpO<SUB>2</SUB>: oxygen saturation; COPD: chronic obstructive pulmonary disease; RR: respiratory rate.<br /><br />* No universally accepted definition of \"severe\" rib fracture exists. An increasing number of fractures and greater fracture complexity (eg, comminution, displacement) increases the risk of complications, but other factors (eg, comorbidity) are important. Refer to the UpToDate topic for additional details.<br />¶ 65 years is a somewhat arbitrary admission threshold. However, older patients are at increased risk of complications from rib fractures. Frail older adults with comorbidities may be candidates for ICU admission even if they do not meet any explicit ICU admission criteria.<br />Δ Refer to UpToDate topics discussing management of rib fractures for details about disposition and discharge criteria.</div><div id=\"graphicVersion\">Graphic 117179 Version 1.0</div></div></div>"},"117180":{"type":"graphic_diagnosticimage","displayName":"Single venous lake in normal placenta","title":"Single venous lake in a normal placenta","html":"<div class=\"graphic\"><div style=\"width: 617px\" class=\"figure\"><div class=\"ttl\">Single venous lake in a normal placenta</div><div class=\"cntnt\"><img style=\"width:597px; height:443px;\" src=\"images/OBGYN/117180_Snglvnouslknrmlplacenta.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">A normal placenta can have vascular lakes, typically a few small, sonolucent spaces with a regular shape and normal underlying myometrial thickness.</div><div class=\"graphic_reference\">Courtesy of Deborah Levine, MD.</div><div id=\"graphicVersion\">Graphic 117180 Version 1.0</div></div></div>"},"117181":{"type":"graphic_diagnosticimage","displayName":"Multiple, irregular placental lacunae in placenta accreta","title":"Multiple, irregular placental lacunae in placenta accreta","html":"<div class=\"graphic\"><div style=\"width: 722px\" class=\"figure\"><div class=\"ttl\">Multiple, irregular placental lacunae in placenta accreta</div><div class=\"cntnt\"><img style=\"width:702px; height:651px;\" src=\"images/OBGYN/117181_Mltpirglrpltlcnpltacrt.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The placental lacunae in placenta accreta are numerous, irregular in shape, and the underlying myometrium may be thinned.</div><div class=\"graphic_reference\">Courtesy of Deborah Levine, MD.</div><div id=\"graphicVersion\">Graphic 117181 Version 1.0</div></div></div>"},"117183":{"type":"graphic_figure","displayName":"Testosterone rx in anemia of known cause","title":"Association of testosterone versus placebo treatment in TTrials participants with anemia of known cause at baseline","html":"<div class=\"graphic\"><div style=\"width: 595px\" class=\"figure\"><div class=\"ttl\">Association of testosterone versus placebo treatment in TTrials participants with anemia of known cause at baseline</div><div class=\"cntnt\"><img style=\"width:575px; height:430px;\" src=\"images/ENDO/117183_Teststrrxanemiaknwncaus.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Results in men with anemia of known causes, shown as dichotomous variables (ie, the percent of men who demonstrated an increase above baseline of 1 g/dL or more). The values are means±pointwise confidence intervals.</div><div class=\"graphic_footnotes\">TTrials: Testosterone Trials.</div><div class=\"graphic_reference\">Reproduced with permission from: Roy CN, Snyder PJ, Stephens-Shields AJ, et al. Association of testosterone levels with anemia in older men: A controlled clinical trial. JAMA Intern Med 2017; 177(4):480-90. Copyright © 2017 American Medical Association. All rights reserved.</div><div id=\"graphicVersion\">Graphic 117183 Version 1.0</div></div></div>"},"117184":{"type":"graphic_figure","displayName":"Testosterone rx effects on bone strength","title":"Effects of testosterone or placebo treatment for 12 months on estimated bone strength","html":"<div class=\"graphic\"><div style=\"width: 602px\" class=\"figure\"><div class=\"ttl\">Effects of testosterone or placebo treatment for 12 months on estimated bone strength</div><div class=\"cntnt\"><img style=\"width:582px; height:369px;\" src=\"images/ENDO/117184_Teststrrxeffsbonestrgth.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Bars indicate means, and error bars indicate standard deviations. The p values indicate the significance of the difference in change in estimated bone strength from baseline to 12 months for men in the testosterone arm compared with the placebo arm.</div><div class=\"graphic_reference\">Reproduced with permission from: Snyder PJ, Kopperdahl DL, Stephens-Shields, AJ, et al. Effect of testosterone treatment on volumetric bone density and strength in older men with low testosterone: A controlled clinical trial. JAMA Intern Med 2017; 177(4):471-79. Copyright © 2017 American Medical Association. All rights reserved.</div><div id=\"graphicVersion\">Graphic 117184 Version 1.0</div></div></div>"},"117209":{"type":"graphic_algorithm","displayName":"Approach to the pregnant and postpartum woman with APS","title":"Approach to the pregnant and postpartum woman with antiphospholipid syndrome or antiphospholipid antibodies","html":"<div class=\"graphic\"><div style=\"width: 564px\" class=\"figure\"><div class=\"ttl\">Approach to the pregnant and postpartum woman with antiphospholipid syndrome or antiphospholipid antibodies</div><div class=\"cntnt\"><img style=\"width:544px; height:677px;\" src=\"images/RHEUM/117209_ApprprgnntptprtmwmnAPS.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This algorithm excludes patients with CAPS, a potentially life-threatening condition involving three or more new organ thromboses within a week in the setting of aPL (refer to UpToDate content on CAPS). Patients with aPL in the setting of SLE should also receive appropriate treatment of SLE regardless of aPL status.</div><div class=\"graphic_footnotes\">aPL: antiphospholipid antibody; LMWH: low molecular weight heparin; ASA: acetylsalicylic acid; APS: antiphospholipid syndrome; CAPS: catastrophic antiphospholipid antibody syndrome; SLE: systemic lupus erythematosus.<br />* Patients with suspected APS should have testing for lupus anticoagulant, anticardiolipin antibodies, and anti-beta2-glycoprotein I antibodies. For those in whom one of the antibodies is detected, testing should be repeated in 12 or more weeks. Refer to UpToDate content on aPL testing.<br />&para; The anticoagulation regimen is the same, regardless of whether or not the woman has a history of an APS-defining pregnancy morbidity.<br />&Delta; APS-defining pregnancy morbidity includes &ge;1 fetal losses at &ge;10 weeks of gestation, &ge;1 preterm deliveries of a morphologically normal infant before 34 weeks of gestation due to severe preeclampsia, eclampsia, or other findings consistent with placental insufficiency, or &ge;3 unexplained consecutive spontaneous pregnancy losses &lt;10 weeks of gestation.<br /><span class=\"lozenge\">&loz;</span> Antithrombotic management differs in cases of ASA failure or when placental examination shows extensive decidual inflammation and vasculopathy and/or thrombosis. Refer to UpToDate content on pregnancy and APS.</div><div id=\"graphicVersion\">Graphic 117209 Version 1.0</div></div></div>"},"117224":{"type":"graphic_table","displayName":"Cysticercosis neuroimaging classification","title":"Classification of neurocysticercosis based on location and appearance of the parasite and surrounding host tissue on neuroimaging","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Classification of neurocysticercosis based on location and appearance of the parasite and surrounding host tissue on neuroimaging</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup width=\"20%\"></colgroup><colgroup width=\"40%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Form*</td> <td class=\"subtitle1\">Characteristic on neuroimaging</td> <td class=\"subtitle1\">Histopathology</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"3\">Parenchymal<sup>&#182;</sup></td> </tr> <tr> <td class=\"indent1\">Nonviable calcified</td> <td>Nodular calcifications &#60;20 mm in diameter (often 1 to 5 mm) with or without surrounding edema and/or contrast enhancement.</td> <td>Calcified granuloma with or without surrounding inflammation and/or gliosis.</td> </tr> <tr> <td class=\"indent1\">Single, small enhancing</td> <td>Cystic or nodular enhancing lesion &#60;2 cm in size.</td> <td>Single parenchymal parasites in the process of degeneration with surrounding inflammation and variable opacification or absence of the cyst fluid.</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Viable parenchymal</td> <td>Vesicular lesions often with evidence of associated contrast enhancement and/or surrounding edema. The scolex is often visible on high-definition imaging.</td> <td>Parasites with intact cyst wall, vesicular fluid, and scolex, with variable amounts of inflammation surrounding the parasite sometimes invading the cyst wall.</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"3\">Extraparenchymal<sup>&#916;</sup></td> </tr> <tr> <td class=\"indent1\">Intraventricular</td> <td>Cysticerci within the ventricles, obstructive hydrocephalus or loculated hydrocephalus with disproportionate dilatation of the ventricles in CT/MRI (suggestive of a cysticercus).</td> <td>Viable cysticercus cyst within the ventricle and/or obstructive hydrocephalus.</td> </tr> <tr> <td class=\"indent1\">Subarachnoid</td> <td>Cysticerci in the Sylvian fissure, in the basilar cisterns, or interhemispheric spaces. Strokes or meningitis without discrete cysts.</td> <td>Cysticerci in the subarachnoid space often with arachnoiditis, vasculitis. The cysticerci are often in clusters with proliferating membranes (racemose) and may lack a scolex.</td> </tr> <tr> <td class=\"indent1\">Spinal</td> <td>Cysticerci within the spinal subarachnoid space with or without evidence of inflammation/diffuse spinal arachnoiditis. Intramedullary cysticerci within the spinal cord.</td> <td>Subarachnoid cysticerci often with associated arachnoiditis. Intramedullary cysticerci similar pathologically to parenchymal cysticerci.</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">CT: computed tomography; MRI: magnetic resonance imaging.<br />* Patients with more than one form are classified with the form found lower on the chart, with the exception that single enhancing lesions that are also viable are grouped with single enhancing lesions. Ocular cysticercosis is classified separately.<br />¶ Refers to cysticerci in the brain parenchyma. Small cysticerci in the gyri over the cerebral convexity behave clinically like parenchymal cysticerci and are grouped with parenchymal cysticerci. Rare forms of neurocysticercosis include multiple inflamed parenchymal cysticerci with diffuse cerebral edema, termed cysticercal encephalitis, large parenchymal cysticerci (&gt;20 mm).<br />Δ Refers to cysticerci in the central nervous system outside of the brain parenchyma.</div><div class=\"graphic_reference\">Reproduced from: White AC Jr, Coyle CM, Rajshekhar V, et al. Diagnosis and treatment of neurocysticercosis: 2017 clinical practice guidelines by the Infectious Diseases Society of America (IDSA) and the American Society of Tropical Medicine and Hygiene (ASTMH). Clin Infect Dis 2018, by permission of Oxford University Press on behalf of IDSA and ASTMH. Copyright © 2018. <A spellcheck=true href=\"http://www.idsociety.org/Guidelines/Patient_Care/IDSA_Practice_Guidelines/Infections_By_Organism-28143/Parasites/Cysticercosis/\" target=_blank>http://www.idsociety.org/Guidelines/Patient_Care/IDSA_Practice_Guidelines/Infections_By_Organism-28143/Parasites/Cysticercosis/</A>.</div><div id=\"graphicVersion\">Graphic 117224 Version 2.0</div></div></div>"},"117234":{"type":"graphic_table","displayName":"Indications for catheter ablation of arrhythmias","title":"Indications for catheter ablation of arrhythmias<sup>[1-3]</sup>","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Indications for catheter ablation of arrhythmias<sup>[1-3]</sup></div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1_single\">Class I</td> </tr> <tr> <td class=\"indent1\"> <ul> <li>Paroxysmal SVT </li> </ul> </td> </tr> <tr> <td class=\"indent1\"> <ul> <li>Symptomatic or medical refractory typical atrial flutter</li> </ul> </td> </tr> <tr> <td class=\"indent1\"> <ul> <li>Symptomatic WPW</li> </ul> </td> </tr> <tr> <td class=\"indent1\"> <ul> <li>Symptomatic PAF refractory to at least one class I/III drug</li> </ul> </td> </tr> <tr> <td class=\"indent1\"> <ul> <li>Symptomatic VPBs in the setting of structurally normal heart </li> </ul> </td> </tr> <tr> <td class=\"indent1\"> <ul> <li>VPB-induced cardiomyopathy </li> </ul> </td> </tr> <tr> <td class=\"indent1\"> <ul> <li>Idiopathic VF induced by unifocal VPBs </li> </ul> </td> </tr> <tr> <td class=\"indent1\"> <ul> <li>Idiopathic VT </li> </ul> </td> </tr> <tr> <td class=\"indent1\"> <ul> <li>Bundle-branch reentrant VT </li> </ul> </td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\"> <ul> <li>Recurrent VT in ischemic cardiomyopathy refractory to amiodarone </li> </ul> </td> </tr> <tr> <td class=\"subtitle1_single\">Class IIa</td> </tr> <tr> <td class=\"indent1\"> <ul> <li>Asymptomatic WPW with high-risk features or high-risk occupation</li> </ul> </td> </tr> <tr> <td class=\"indent1\"> <ul> <li>Symptomatic PAF prior to treatment with class I/III drug </li> </ul> </td> </tr> <tr> <td class=\"indent1\"> <ul> <li>Symptomatic persistent AF refractory to at least one class I/III drug or prior to class I/III drug</li> </ul> </td> </tr> <tr> <td class=\"indent1\"> <ul> <li>Recurrent VT in NICM refractory to antiarrhythmic therapy</li> </ul> </td> </tr> <tr> <td class=\"indent1\"> <ul> <li>Recurrent VT in adult congenital heart disease refractory to antiarrhythmic therapy</li> </ul> </td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\"> <ul> <li>Recurrent VT in ARVC refractory to beta blocker </li> </ul> </td> </tr> <tr> <td class=\"subtitle1_single\">Class IIb</td> </tr> <tr> <td class=\"indent1\"> <ul> <li>Long-standing symptomatic persistent AF</li> </ul> </td> </tr> <tr> <td class=\"indent1\"> <ul> <li>Select asymptomatic AF </li> </ul> </td> </tr> <tr> <td class=\"indent1\"> <ul> <li>Recurrent VT in ischemic cardiomyopathy as an alternative to pharmacologic therapy </li> </ul> </td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">SVT: supraventricular tachycardia; WPW: Wolff-Parkinson-White syndrome; PAF: paroxysmal atrial fibrillation; VPB: ventricular premature beat; VF: ventricular fibrillation; VT: ventricular tachycardia; AF: atrial fibrillation; NICM: nonischemic cardiomyopathy; ARVC: arrhythmogenic right ventricular cardiomyopathy.</div><div class=\"graphic_reference\">References:&#xD;&#xA;<ol>&#xD;&#xA;    <li>Al-Khatib SM, Stevenson WG, Ackerman MJ, et al. 2017 AHA/ACC/HRS Guideline for Management of Patients With Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Rhythm Society. J Am Coll Cardiol 2017.</li>&#xD;&#xA;    <li>Calkins H, Hindricks G, Cappato R, et al. 2017 HRS/EHRA/ECAS/APHRS/SOLAECE expert consensus statement on catheter and surgical ablation of atrial fibrillation. Heart Rhythm 2017; 14:e275.</li>&#xD;&#xA;    <li>Page RL, Joglar JA, Caldwell MA, et al. 2015 ACC/AHA/HRS Guideline for the Management of Adult Patients With Supraventricular Tachycardia: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Rhythm Society. J Am Coll Cardiol 2016; 67:e27.</li>&#xD;&#xA;</ol></div><div id=\"graphicVersion\">Graphic 117234 Version 1.0</div></div></div>"},"117235":{"type":"graphic_table","displayName":"Treatment of Clostridium difficile infection in children","title":"Treatment of <em>Clostridium difficile</em> infection in children","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Treatment of <em>Clostridium difficile</em> infection in children</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup width=\"25%\"></colgroup><colgroup width=\"75%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Clinical features</td> <td class=\"subtitle1\">Suggested treatment</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"2\">First episode</td> </tr> <tr> <td class=\"indent1\">Mild or moderate</td> <td> <ul> <li>Vancomycin 40 mg/kg per day orally divided in four doses (maximum dose: 125 mg) for 10 days, <strong>or</strong> </li> <li>Metronidazole 30 mg/kg per day orally divided in four doses (maximum dose: 500 mg) for 10 days </li> </ul> </td> </tr> <tr> <td class=\"indent1\">Severe*</td> <td> <ul> <li>Vancomycin 40 mg/kg per day orally divided in four doses (maximum dose: 125 mg) for 10 days </li> </ul> </td> </tr> <tr> <td class=\"indent1\">Fulminant<sup>&#182;</sup></td> <td> <ul> <li>Vancomycin 40 mg/kg per day orally divided in four doses (maximum dose: 500 mg) until clinical improvement and then (if applicable) decrease the maximum dose to 125 mg to complete 10 days </li> </ul> </td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Fulminant<sup>&#182;</sup> disease and ileus</td> <td> <ul> <li>Metronidazole 30 mg/kg per day IV divided in four doses (maximum dose: 500 mg), <strong>plus</strong> </li> <li>Vancomycin 10 mg/kg per dose in normal saline (maximum dose: 500 mg in 100 mL normal saline) administered by retention enema four times per day<sup>&#916;</sup>; the volume of solution varies with age: <ul> <li>1 through 4 years: 50 mL </li> <li>5 through 11 years: 75 mL </li> <li>&#8805;12 years: 100 mL </li> </ul> </li> </ul> </td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"2\">Recurrent episodes</td> </tr> <tr> <td class=\"indent1\">First recurrence, mild or moderate</td> <td> <ul> <li>Repeat regimen used for first episode </li> </ul> </td> </tr> <tr> <td class=\"indent1\">Subsequent recurrence, mild or moderate</td> <td> <ul> <li>Pulsed-tapered vancomycin (maximum dose: 125 mg): <ul> <li>10 mg/kg orally four times daily for 10 to 14 days, followed by </li> <li>10 mg/kg orally twice daily for 7 days, followed by </li> <li>10 mg/kg orally once daily for 7 days, followed by </li> <li>10 mg/kg orally every other day for 7 days, followed by </li> <li>10 mg/kg orally every 3 days for 2 to 8 weeks </li> </ul> </li> </ul> </td> </tr> </tbody></table></div><div class=\"graphic_lgnd\">This table is meant to be used in conjunction with the UpToDate topic on treatment of <em>C. difficile</em> infection in children.</div><div class=\"graphic_footnotes\">IV: intravenous.<br />* There is no consensus definition of severe <em>C. difficile</em> infection in children. Determination of disease severity should be guided by clinician judgment. We use the following criteria to define severe disease: Fever, profuse diarrhea, abdominal pain and tenderness, abdominal distention, white blood cell count &gt;15,000 cells/microL, elevated age-adjusted creatinine level, serum albumin &lt;2.5 g/dL (25 g/L), and pseudomembranous colitis.<br />&para; Fulminant disease is characterized by hypotension, shock, ileus, or toxic megacolon.<br />&Delta; The optimal dose and volume for rectal vancomycin has not been established for children or adults. Dose and volume adjustments may be required depending upon individual circumstances, extent of colonic disease, and patient weight. Caution is required because perforation is possible with rectal installation of vancomycin.</div><div class=\"graphic_reference\">Adapted from: McDonald LC, Gerding DN, Johnson S, et al. Clinical practice guidelines for Clostridium difficile infection in adults and children: 2017 update by the Infectious Diseases Society of America (IDSA) and Society for Healthcare Epidemiology of America (SHEA). Clin Infect Dis 2018.</div><div id=\"graphicVersion\">Graphic 117235 Version 1.0</div></div></div>"},"117272":{"type":"graphic_algorithm","displayName":"Management of OME in children","title":"Our approach to the management of otitis media with effusion (OME) in children","html":"<div class=\"graphic\"><div style=\"width: 638px\" class=\"figure\"><div class=\"ttl\">Our approach to the management of otitis media with effusion (OME) in children</div><div class=\"cntnt\"><img style=\"width:618px; height:820px;\" src=\"images/PEDS/117272_ManagementOMEchildren.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This algorithm is intended for use in conjunction with UpToDate content on OME in children.</div><div class=\"graphic_footnotes\">OME: otitis media with effusion; ASD: autism spectrum disorder; ORL/ENT: otolaryngology/ear, nose, and throat; TM: tympanic membrane; AOM: acute otitis media; dB: decibels.<br />* Refer to UpToDate content on hearing evaluation in children for details.<br />¶ Patients and families should be counseled that OME may be associated with conductive hearing loss that can be addressed through speaking in close proximity to the child, facing the child and speaking clearly, repeating phrases when misunderstood, providing preferential classroom seating, and/or having the teacher use a frequency modulated (FM) system in the classroom.<br />Δ Refer to UpToDate content on developmental screening and surveillance for details.<br /><FONT class=lozenge>◊</FONT> Refer to UpToDate content on management of OME in children for details.<br />§ Repeat hearing evaluation may be warranted for parental concerns about hearing loss. Following resolution of OME, routine developmental/language surveillance and screening should continue as scheduled with health maintenance visits.</div><div class=\"graphic_reference\">Adapted from: Rosenfeld RM, Shin JJ, Schwartz SR, et al. Clinical practice guideline: Otitis media with effusion (update). Otolaryngol Head Neck Surg 2016; 154:S1.</div><div id=\"graphicVersion\">Graphic 117272 Version 1.0</div></div></div>"},"117309":{"type":"graphic_algorithm","displayName":"Algorithm medical management of patients with ARVC","title":"Algorithm showing the approach to medical management of patients with ARVC*","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Algorithm showing the approach to medical management of patients with ARVC*</div><div class=\"cntnt\"><img style=\"width:344px; height:763px;\" src=\"images/CARD/117309_MedicalmgmtpatientsARVC.gif\" alt=\"Image\"/></div><div class=\"graphic_footnotes\">ARVC: arrhythmogenic right ventricular cardiomyopathy; ICD: implantable cardioverter-defibrillator; LV: left ventricular; ACE: angiotensin converting enzyme; ARB: angiotensin II receptor blocker.<br />* All patients with definite ARVC should be restricted from vigorous activity, and first degree relatives of the proband should be screened. Refer to UpToDate topic on ARVC treatment for additional details.<br />&para; All patients should have been evaluated for risk of sudden cardiac death and potential need for an ICD prior to medical therapy.<br />&Delta; Antiarrhythmic drug options in ARVC include sotalol, flecainide, and amiodarone. Refer to UpToDate topic on ARVC treatment for additional details.<br /><span class=\"lozenge\">&loz;</span> If patient has ventricular arrhythmias and has not had an ICD, referral for ICD implantation should occur.<br />&sect; Refer to UpToDate topics on treatment of heart failure with reduced LV function. Standard heart failure therapy may include beta blocker, ACE inhibitor or ARB, aldosterone antagonist, and diuretics.</div><div id=\"graphicVersion\">Graphic 117309 Version 3.0</div></div></div>"},"117315":{"type":"graphic_table","displayName":"NCI CTCAE v5 arterial thromboembolism","title":"NCI CTCAE v5.0 arterial thromboembolism","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">NCI CTCAE v5.0 arterial thromboembolism</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"6\" width=\"16%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Adverse event</td> <td class=\"subtitle1\">Grade 1</td> <td class=\"subtitle1\">Grade 2</td> <td class=\"subtitle1\">Grade 3</td> <td class=\"subtitle1\">Grade 4</td> <td class=\"subtitle1\">Grade 5</td> </tr> <tr> <td>Arterial thromboembolism</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>Urgent intervention indicated</td> <td>Life-threatening consequences; hemodynamic or neurologic instability; organ damage; loss of extremity(ies)</td> <td>Death</td> </tr> </tbody></table></div><div class=\"graphic_lgnd\">Arterial thromboembolism is characterized by occlusion of an arterial vessel by a blood clot that develops in an artery.</div><div class=\"graphic_footnotes\">NCI CTCAE: National Cancer Institute Common Terminology Criteria for Adverse Events.</div><div class=\"graphic_reference\">Reproduced from: Common Terminology Criteria for Adverse Events (CTCAE), Version 5.0, November 2017, National Institutes of Health, National Cancer Institute. Available at: <a href=\"https://ctep.cancer.gov/protocoldevelopment/electronic_applications/docs/CTCAE_v5_Quick_Reference_8.5x11.pdf\" target=\"_blank\">https://ctep.cancer.gov/protocoldevelopment/electronic_applications/docs/CTCAE_v5_Quick_Reference_8.5x11.pdf</a> (Accessed March 27, 2018).</div><div id=\"graphicVersion\">Graphic 117315 Version 1.0</div></div></div>"},"117316":{"type":"graphic_table","displayName":"NCI CTCAE v5 SVC syndrome","title":"NCI CTCAE v5.0 superior vena cava (SVC) syndrome","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">NCI CTCAE v5.0 superior vena cava (SVC) syndrome</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"6\" width=\"16%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Adverse event</td> <td class=\"subtitle1\">Grade 1</td> <td class=\"subtitle1\">Grade 2</td> <td class=\"subtitle1\">Grade 3</td> <td class=\"subtitle1\">Grade 4</td> <td class=\"subtitle1\">Grade 5</td> </tr> <tr> <td>Superior vena cava (SVC) syndrome</td> <td>Asymptomatic; incidental finding of SVC thrombosis</td> <td>Symptomatic, medical intervention indicated (eg, anticoagulation, radiation, or chemotherapy)</td> <td>Severe symptoms; multimodality intervention indicated (eg, anticoagulation, chemotherapy, radiation, stenting)</td> <td>Life-threatening consequences; urgent multimodality intervention indicated (eg, lysis, thrombectomy, surgery)</td> <td>Death</td> </tr> </tbody></table></div><div class=\"graphic_lgnd\">SVC syndrome is characterized by obstruction of the blood flow in the SVC. Signs and symptoms include swelling and cyanosis of the face, neck, and upper arms, cough, orthopnea, and headache.</div><div class=\"graphic_footnotes\">NCI CTCAE: National Cancer Institute Common Terminology Criteria for Adverse Events; SVC: superior vena cava.</div><div class=\"graphic_reference\">Reproduced from: Common Terminology Criteria for Adverse Events (CTCAE), Version 5.0, November 2017, National Institutes of Health, National Cancer Institute. Available at: <a href=\"https://ctep.cancer.gov/protocoldevelopment/electronic_applications/docs/CTCAE_v5_Quick_Reference_8.5x11.pdf\" target=\"_blank\">https://ctep.cancer.gov/protocoldevelopment/electronic_applications/docs/CTCAE_v5_Quick_Reference_8.5x11.pdf</a> (Accessed March 27, 2018).</div><div id=\"graphicVersion\">Graphic 117316 Version 1.0</div></div></div>"},"117317":{"type":"graphic_table","displayName":"NCI CTCAE v5 thrombotic thrombocytopenic purpura","title":"NCI CTCAE v5.0 thrombotic thrombocytopenic purpura","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">NCI CTCAE v5.0 thrombotic thrombocytopenic purpura</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"6\" width=\"16%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Adverse event</td> <td class=\"subtitle1\">Grade 1</td> <td class=\"subtitle1\">Grade 2</td> <td class=\"subtitle1\">Grade 3</td> <td class=\"subtitle1\">Grade 4</td> <td class=\"subtitle1\">Grade 5</td> </tr> <tr> <td>Thrombotic thrombocytopenic purpura</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>Laboratory findings with clinical consequences (eg, renal insufficiency, petechiae)</td> <td>Life-threatening consequences (eg, CNS hemorrhage or thrombosis/embolism or renal failure)</td> <td>Death</td> </tr> </tbody></table></div><div class=\"graphic_lgnd\">Thrombotic thrombocytopenic purpura is a disorder characterized by the presence of microangiopathic hemolytic anemia, thrombocytopenic purpura, fever, renal abnormalities, and neurologic abnormalities such as seizures, hemiplegia, and visual disturbances. It is an acute or subacute condition.</div><div class=\"graphic_footnotes\">NCI CTCAE: National Cancer Institute Common Terminology Criteria for Adverse Events; CNS: central nervous system.</div><div class=\"graphic_reference\">Reproduced from: Common Terminology Criteria for Adverse Events (CTCAE), Version 5.0, November 2017, National Institutes of Health, National Cancer Institute. Available at: <a href=\"https://ctep.cancer.gov/protocoldevelopment/electronic_applications/docs/CTCAE_v5_Quick_Reference_8.5x11.pdf\" target=\"_blank\">https://ctep.cancer.gov/protocoldevelopment/electronic_applications/docs/CTCAE_v5_Quick_Reference_8.5x11.pdf</a> (Accessed March 27, 2018).</div><div id=\"graphicVersion\">Graphic 117317 Version 1.0</div></div></div>"},"117318":{"type":"graphic_table","displayName":"NCI CTCAE v5 hemolytic uremic syndrome","title":"NCI CTCAE v5.0 hemolytic uremic syndrome","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">NCI CTCAE v5.0 hemolytic uremic syndrome</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"6\" width=\"16%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Adverse event</td> <td class=\"subtitle1\">Grade 1</td> <td class=\"subtitle1\">Grade 2</td> <td class=\"subtitle1\">Grade 3</td> <td class=\"subtitle1\">Grade 4</td> <td class=\"subtitle1\">Grade 5</td> </tr> <tr> <td>Hemolytic uremic syndrome</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>Laboratory findings with clinical consequences (eg, renal insufficiency, petechiae)</td> <td>Life-threatening consequences (eg, CNS hemorrhage or thrombosis/embolism or renal failure)</td> <td>Death</td> </tr> </tbody></table></div><div class=\"graphic_lgnd\">Hemolytic uremic syndrome is characterized by a form of thrombotic microangiopathy with renal failure, hemolytic anemia, and severe thrombocytopenia.</div><div class=\"graphic_footnotes\">NCI CTCAE: National Cancer Institute Common Terminology Criteria for Adverse Events; CNS: central nervous system.</div><div class=\"graphic_reference\">Reproduced from: Common Terminology Criteria for Adverse Events (CTCAE), Version 5.0, November 2017, National Institutes of Health, National Cancer Institute. Available at: <a href=\"https://ctep.cancer.gov/protocoldevelopment/electronic_applications/docs/CTCAE_v5_Quick_Reference_8.5x11.pdf\" target=\"_blank\">https://ctep.cancer.gov/protocoldevelopment/electronic_applications/docs/CTCAE_v5_Quick_Reference_8.5x11.pdf</a> (Accessed March 27, 2018).</div><div id=\"graphicVersion\">Graphic 117318 Version 1.0</div></div></div>"},"117320":{"type":"graphic_table","displayName":"NCI CTCAE v5 constipation","title":"NCI CTCAE v5.0 constipation","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">NCI CTCAE v5.0 constipation</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"6\" width=\"16%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Adverse event</td> <td class=\"subtitle1\">Grade 1</td> <td class=\"subtitle1\">Grade 2</td> <td class=\"subtitle1\">Grade 3</td> <td class=\"subtitle1\">Grade 4</td> <td class=\"subtitle1\">Grade 5</td> </tr> <tr> <td>Constipation</td> <td>Occasional or intermittent symptoms; occasional use of stool softeners, laxatives, dietary modification, or enema</td> <td>Persistent symptoms with regular use of laxatives or enemas; limiting instrumental ADL*</td> <td>Obstipation with manual evacuation indicated; limiting self-care ADL*</td> <td>Life-threatening consequences; urgent intervention indicated</td> <td>Death</td> </tr> </tbody></table></div><div class=\"graphic_lgnd\">Constipation is characterized by irregular and infrequent or difficult evacuation of the bowels.</div><div class=\"graphic_footnotes\">NCI CTCAE: National Cancer Institute Common Terminology Criteria for Adverse Events; ADL: activities of daily living.<br />* Instrumental ADLs include preparing meals, shopping, using the telephone, managing money. Self-care ADLs include bathing, dressing/undressing, using the toilet, taking medications, and not bedridden.</div><div class=\"graphic_reference\">Reproduced from: Common Terminology Criteria for Adverse Events (CTCAE), Version 5.0, November 2017, National Institutes of Health, National Cancer Institute. Available at: <a href=\"https://ctep.cancer.gov/protocoldevelopment/electronic_applications/docs/CTCAE_v5_Quick_Reference_8.5x11.pdf\" target=\"_blank\">https://ctep.cancer.gov/protocoldevelopment/electronic_applications/docs/CTCAE_v5_Quick_Reference_8.5x11.pdf</a> (Accessed March 27, 2018).</div><div id=\"graphicVersion\">Graphic 117320 Version 1.0</div></div></div>"},"117321":{"type":"graphic_table","displayName":"NCI CTCAE v5 dyspnea","title":"NCI CTCAE v5.0 dyspnea","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">NCI CTCAE v5.0 dyspnea</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"6\" width=\"16%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Adverse event</td> <td class=\"subtitle1\">Grade 1</td> <td class=\"subtitle1\">Grade 2</td> <td class=\"subtitle1\">Grade 3</td> <td class=\"subtitle1\">Grade 4</td> <td class=\"subtitle1\">Grade 5</td> </tr> <tr> <td>Dyspnea</td> <td>Shortness of breath with moderate exertion</td> <td>Shortness of breath with minimal exertion; limiting instrumental ADL*</td> <td>Shortness of breath at rest; limiting self-care ADL*</td> <td>Life-threatening consequences; urgent intervention indicated</td> <td>Death</td> </tr> </tbody></table></div><div class=\"graphic_lgnd\">Dyspnea is characterized by an uncomfortable sensation of difficulty breathing.</div><div class=\"graphic_footnotes\">NCI CTCAE: National Cancer Institute Common Terminology Criteria for Adverse Events; ADL: activities of daily living.<br />* Instrumental ADLs include preparing meals, shopping, using the telephone, managing money. Self-care ADLs include bathing, dressing, using the toilet, taking medications.</div><div class=\"graphic_reference\">Reproduced from: Common Terminology Criteria for Adverse Events (CTCAE), Version 5.0, November 2017, National Institutes of Health, National Cancer Institute. Available at: <a href=\"https://ctep.cancer.gov/protocoldevelopment/electronic_applications/docs/CTCAE_v5_Quick_Reference_8.5x11.pdf\" target=\"_blank\">https://ctep.cancer.gov/protocoldevelopment/electronic_applications/docs/CTCAE_v5_Quick_Reference_8.5x11.pdf</a> (Accessed March 27, 2018).</div><div id=\"graphicVersion\">Graphic 117321 Version 1.0</div></div></div>"},"117322":{"type":"graphic_table","displayName":"NCI CTCAE v5 esophagitis","title":"NCI CTCAE v5.0 esophagitis","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">NCI CTCAE v5.0 esophagitis</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"6\" width=\"16%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Adverse event</td> <td class=\"subtitle1\">Grade 1</td> <td class=\"subtitle1\">Grade 2</td> <td class=\"subtitle1\">Grade 3</td> <td class=\"subtitle1\">Grade 4</td> <td class=\"subtitle1\">Grade 5</td> </tr> <tr> <td>Esophagitis</td> <td>Asymptomatic; clinical or diagnostic observations only; intervention not indicated</td> <td>Symptomatic; altered eating/swallowing; oral supplements indicated</td> <td>Severely altered eating/swallowing; tube feeding, TPN, or hospitalization indicated</td> <td>Life-threatening consequences; urgent operative intervention indicated</td> <td>Death</td> </tr> </tbody></table></div><div class=\"graphic_lgnd\">Esophagitis is characterized by inflammation of the esophageal wall.</div><div class=\"graphic_footnotes\">NCI CTCAE: National Cancer Institute Common Terminology Criteria for Adverse Events; TPN: total parenteral nutrition.</div><div class=\"graphic_reference\">Reproduced from: Common Terminology Criteria for Adverse Events (CTCAE), Version 5.0, November 2017, National Institutes of Health, National Cancer Institute. Available at: <a href=\"https://ctep.cancer.gov/protocoldevelopment/electronic_applications/docs/CTCAE_v5_Quick_Reference_8.5x11.pdf\" target=\"_blank\">https://ctep.cancer.gov/protocoldevelopment/electronic_applications/docs/CTCAE_v5_Quick_Reference_8.5x11.pdf</a> (Accessed March 27, 2018).</div><div id=\"graphicVersion\">Graphic 117322 Version 1.0</div></div></div>"},"117331":{"type":"graphic_waveform","displayName":"TEE mid-esophageal four-chamber MV color Doppler","title":"TEE mid-esophageal four-chamber MV color Doppler","html":"<div class=\"graphic\"><div style=\"width: 738px\" class=\"figure\"><div class=\"ttl\">TEE mid-esophageal four-chamber MV color Doppler</div><div class=\"cntnt\"><img style=\"width:718px; height:561px;\" src=\"images/CARD/117331_TEEmdsphgl4chbrmtrlclr.jpg\" alt=\"Image\"/></div><div class=\"graphic_footnotes\">TEE: transesophageal echocardiography; MV: mitral valve.</div><div id=\"graphicVersion\">Graphic 117331 Version 2.0</div></div></div>"},"117334":{"type":"graphic_waveform","displayName":"TEE mid-esophageal four-chamber Doppler MV inflow","title":"TEE mid-esophageal four-chamber Doppler MV inflow","html":"<div class=\"graphic\"><div style=\"width: 710px\" class=\"figure\"><div class=\"ttl\">TEE mid-esophageal four-chamber Doppler MV inflow</div><div class=\"cntnt\"><img style=\"width:690px; height:716px;\" src=\"images/CARD/117334_TEEmsphgl4chbDplMVnfw.jpg\" alt=\"Image\"/></div><div class=\"graphic_footnotes\">TEE: transesophageal echocardiography; MV: mitral valve.</div><div id=\"graphicVersion\">Graphic 117334 Version 1.0</div></div></div>"},"117341":{"type":"graphic_table","displayName":"NCI CTCAE v5 hearing impaired","title":"NCI CTCAE v5.0 hearing impaired","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">NCI CTCAE v5.0 hearing impaired</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"6\" width=\"16%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Adverse event</td> <td class=\"subtitle1\">Grade 1</td> <td class=\"subtitle1\">Grade 2</td> <td class=\"subtitle1\">Grade 3</td> <td class=\"subtitle1\">Grade 4</td> <td class=\"subtitle1\">Grade 5</td> </tr> <tr> <td>Hearing impaired</td> <td> <p>Adults enrolled on a monitoring program (on a 1, 2, 3, 4, 6, and 8 kHz audiogram): Threshold shift of 15 to 25 dB averaged at two contiguous test frequencies in at least one ear</p> <hr /> <p>Adults not enrolled on a monitoring program: Subjective change in hearing in the absence of documented hearing loss</p> <hr /> Pediatric (on a 1, 2, 3, 4, 6, and 8 kHz audiogram): Threshold shift &#62;20 dB hearing loss (ie, 25 dB hearing loss or greater); sensorineural hearing loss above 4 kHz (ie, 6 or 8 kHz) in at least one ear</td> <td> <p>Adults enrolled on a monitoring program (on a 1, 2, 3, 4, 6, and 8 kHz audiogram): Threshold shift of &#62;25 dB averaged at two contiguous test frequencies in at least one ear</p> <hr /> <p>Adults not enrolled on a monitoring program: Hearing loss with hearing aid or intervention not indicated; limiting instrumental ADL</p> <hr /> Pediatric (on a 1, 2, 3, 4, 6, and 8 kHz audiogram): Threshold shift &#62;20 dB at 2 to &#60;4 kHz in at least one ear</td> <td> <p>Adults enrolled on a monitoring program (on a 1, 2, 3, 4, 6, and 8 kHz audiogram): Threshold shift of &#62;25 dB averaged at three contiguous test frequencies in at least one ear; therapeutic intervention indicated</p> <hr /> <p>Adults not enrolled on a monitoring program: Hearing loss with hearing aid or intervention indicated; limiting self-care ADL</p> <hr /> Pediatric (on a 1, 2, 3, 4, 6, and 8 kHz audiogram): Hearing loss sufficient to indicate therapeutic intervention, including hearing aids; threshold shift &#62;20 dB at 2 to &#60;4 kHz in at least one ear</td> <td> <p>Adults: Decrease in hearing to profound bilateral loss (absolute threshold &#62;80 dB hearing loss at 2 kHz and above); nonservicable hearing</p> <hr /> Pediatric: Audiologic indication for cochlear implant; &#62;40 dB hearing loss (ie, 45 dB hearing loss or more); sensorineural hearing loss at 2 kHz and above</td> <td>&nbsp;</td> </tr> </tbody></table></div><div class=\"graphic_lgnd\">Hearing impairment is characterized by partial or complete loss of the ability to detect or understand sounds resulting from damage to ear structures.</div><div class=\"graphic_footnotes\">NCI CTCAE: National Cancer Institute Common Terminology Criteria for Adverse Events; kHz: kilohertz; dB: decibel; ADL: activities of daily living.</div><div class=\"graphic_reference\">Reproduced from: Common Terminology Criteria for Adverse Events (CTCAE), Version 5.0, November 2017, National Institutes of Health, National Cancer Institute. Available at: <a href=\"https://ctep.cancer.gov/protocoldevelopment/electronic_applications/docs/CTCAE_v5_Quick_Reference_8.5x11.pdf\" target=\"_blank\">https://ctep.cancer.gov/protocoldevelopment/electronic_applications/docs/CTCAE_v5_Quick_Reference_8.5x11.pdf</a> (Accessed March 27, 2018).</div><div id=\"graphicVersion\">Graphic 117341 Version 2.0</div></div></div>"},"117356":{"type":"graphic_table","displayName":"NCI CTCAE v5 serum sickness","title":"NCI CTCAE v5.0 serum sickness","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">NCI CTCAE v5.0 serum sickness</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"6\" width=\"16%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Adverse event</td> <td class=\"subtitle1\">Grade 1</td> <td class=\"subtitle1\">Grade 2</td> <td class=\"subtitle1\">Grade 3</td> <td class=\"subtitle1\">Grade 4</td> <td class=\"subtitle1\">Grade 5</td> </tr> <tr> <td>Serum sickness</td> <td>Asymptomatic; clinical or diagnostic observations only; intervention not indicated</td> <td>Moderate arthralgia; fever, rash, urticaria, antihistamines indicated</td> <td>Severe arthralgia or arthritis; extensive rash; steroids or intravenous fluids indicated</td> <td>Life-threatening consequences; pressor or ventilatory support indicated</td> <td>Death</td> </tr> </tbody></table></div><div class=\"graphic_lgnd\">Serum sickness is characterized by a delayed-type hypersensitivity reaction to foreign proteins derived from an animal serum. It occurs approximately six to twenty-one days following the administration of the foreign antigen. Symptoms include fever, arthralgias, myalgias, skin eruptions, lymphadenopathy, chest marked discomfort, and dyspnea.</div><div class=\"graphic_footnotes\">NCI CTCAE: National Cancer Institute Common Terminology Criteria for Adverse Events.</div><div class=\"graphic_reference\">Reproduced from: Common Terminology Criteria for Adverse Events (CTCAE), Version 5.0, November 2017, National Institutes of Health, National Cancer Institute. Available at: <a href=\"https://ctep.cancer.gov/protocoldevelopment/electronic_applications/docs/CTCAE_v5_Quick_Reference_8.5x11.pdf\" target=\"_blank\">https://ctep.cancer.gov/protocoldevelopment/electronic_applications/docs/CTCAE_v5_Quick_Reference_8.5x11.pdf</a> (Accessed March 27, 2018).</div><div id=\"graphicVersion\">Graphic 117356 Version 1.0</div></div></div>"},"117357":{"type":"graphic_table","displayName":"NCI CTCAE v5 oculomotor nerve disorder","title":"NCI CTCAE v5.0 oculomotor nerve disorder","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">NCI CTCAE v5.0 oculomotor nerve disorder</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"6\" width=\"16%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Adverse event</td> <td class=\"subtitle1\">Grade 1</td> <td class=\"subtitle1\">Grade 2</td> <td class=\"subtitle1\">Grade 3</td> <td class=\"subtitle1\">Grade 4</td> <td class=\"subtitle1\">Grade 5</td> </tr> <tr> <td>Oculomotor nerve disorder</td> <td>Asymptomatic; clinical or diagnostic observations only; interventions not indicated</td> <td>Moderate symptoms; limiting instrumental ADL</td> <td>Severe limitations; limiting self-care ADL</td> <td>&nbsp;</td> <td>&nbsp;</td> </tr> </tbody></table></div><div class=\"graphic_lgnd\">Oculomotor nerve disorder is characterized by dysfunction of the oculomotor nerve (third cranial nerve).</div><div class=\"graphic_footnotes\">NCI CTCAE: National Cancer Institute Common Terminology Criteria for Adverse Events; ADL: activities of daily living.</div><div class=\"graphic_reference\">Reproduced from: Common Terminology Criteria for Adverse Events (CTCAE), Version 5.0, November 2017, National Institutes of Health, National Cancer Institute. Available at: <a href=\"https://ctep.cancer.gov/protocoldevelopment/electronic_applications/docs/CTCAE_v5_Quick_Reference_8.5x11.pdf\" target=\"_blank\">https://ctep.cancer.gov/protocoldevelopment/electronic_applications/docs/CTCAE_v5_Quick_Reference_8.5x11.pdf</a> (Accessed March 29, 2018).</div><div id=\"graphicVersion\">Graphic 117357 Version 1.0</div></div></div>"}};